 
I1F-MC-RHCD(b) Clinical Protocol 
 
 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, 
Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate- to-Severe Plaque Psoriasis. 
 
[STUDY_ID_REMOVED]
 
 
Approval Date: 22- Sep-2018 
 
 
I1F-MC-RHCD (b)Clinical Protocol Page 1
LY2439821Protocol I1F-MC-RHCD (b)
Multicent er, Double -Blind, Randomized, Placebo -Controlled 
Study  to Evaluate Safety , Tolerability , and Efficacy  of 
Ixekizumab in Patients from 6 to Less than 18 Years of A ge 
with Moderate -to-Severe Plaque Psoriasis
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of
ixekizumab (LY2439821), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries .
Note to Regulatory Authorities :  This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Ixekizumab (LY2439821)
Study I1F -MC-RHCD is a Phase 3, multicenter, double -blind ,randomized , placebo -
controlled study examining the effects of ixekizumab versus placebo in subject sfrom 6 to 
<18 years of age with moderate -to-severe plaque psoriasis (P soriasis Area and Severity 
Index score ≥12, sPGA ≥3, and body surface area ≥10% at screening and baseline )and 
including etanercept as a reference group .
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electronically Signed and Approved by Lilly :30 November 2016
Amendm ent (a) Electronically Signed and Approved by Lilly:  20 July 2017
Amendm ent (b) Electronically Signed and Approved by Lilly
on approval date provided below :  
Approval Date: 22-Sep-2018 GMT
I1F-MC-RHCD (b)Clinical Protocol Page 2
LY2439821Table of Contents
Section Page
Protocol  I1F-MC-RHCD(b) Mult icenter, Double -Blind, Rando mized, 
Placebo -Controlled Study  to Eval uate Safet y, Tolerabili ty, and 
Efficacy of Ixekizumab in Pat ients from 6 to Less than 18 Years of 
Age wit h Moderate -to-Severe Plaque Psori asis................................................................... 1
Table of Contents ........................................................................................................................ 2
1. Synopsis ............................................................................................................................. 9
2. Schedule of Act ivities....................................................................................................... 13
3. Introduction ...................................................................................................................... 25
3.1. Study  Rati onale ............................................................................................................ 25
3.2. Background .................................................................................................................. 25
3.3. Benefit/Risk Assessment .............................................................................................. 26
4. Object ives and Endpo ints.................................................................................................. 27
5. Study  Design ..................................................................................................................... 29
5.1. Overall Design ............................................................................................................. 29
5.1.1. S creening Period (Period 1) .................................................................................. 33
5.1.2. 12- Week Double -Blind Treatm ent Inducti on Peri od (Peri od 
2)......................................................................................................................... 33
5.1.3.
48-Week Open -Label  Maintenance Peri od (Peri od 3) ........................................... 34
5.1.4.
48-Week Extensio n Peri od (Peri od 4) ................................................................... 34
5.1.5. Post-Treatment Follow -Up Peri od (Peri od 5) ....................................................... 34
5.2. Number of Participants .................................................................................................35
5.3. End of Study  Definit ion............................................................................................... 35
5.4. Scientific Rationale for Study  Design ........................................................................... 35
5.5. Justification for Dose ................................................................................................... 36
6. Study  Popul ation............................................................................................................... 37
6.1. Inclusio n Cri teria.......................................................................................................... 37
6.2. Exclusio n Cri teria........................................................................................................ 38
6.3. Lifest yle Restrict ions.................................................................................................... 42
6.4. Screen Failures ............................................................................................................. 42
7. Treat ments ........................................................................................................................ 43
7.1. Treatments Administered ............................................................................................. 43
7.1.1. Packaging and Labeling ....................................................................................... 44
7.2. Method of Treatment Assignment ................................................................................ 44
7.2.1. Selection and Timing o f Doses ............................................................................. 45
7.3. Blinding ....................................................................................................................... 45
I1F-MC-RHCD (b)Clinical Protocol Page 3
LY24398217.4. Dosage Modification .................................................................................................... 45
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 46
7.6. Treatment Compliance .................................................................................................46
7.7. Concomitant Therapy ................................................................................................... 46
7.8. Treatment after the End of the Study ............................................................................ 47
7.8.1. Continued Access .................................................................................................47
7.8.2. Speci al Treatm ent Consi derat ions........................................................................ 48
7.8.3. Perm anent Discont inuat ion from Study Treatment ............................................... 49
8. Discontinuati on Cri teria .................................................................................................... 51
8.1. Discontinuati on from Study  Treatm ent......................................................................... 51
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects .............................................. 51
8.2. Discontinuati on from the Study .................................................................................... 51
8.3. Lost to Follow -Up........................................................................................................ 52
9. Study  Assessments and Procedures ................................................................................... 53
9.1. Efficacy Assessments ................................................................................................... 53
9.1.1. Primary Efficacy  Assessments ............................................................................. 53
9.1.2. Secondary  Efficacy  Assessments .......................................................................... 53
9.1.2.1. Nail Psoriasis Severit y Index (NAPSI) ............................................................ 53
9.1.2.2. Psori asis Scalp Severit y Index........................................................................ 54
9.1.2.3. Palmoplantar Psoriasis Area and Severit y Index ............................................. 54
9.1.2.4. Percentage of Body  Surf ace Area ................................................................... 54
9.1.2.5. Binary Quest ions on Psoriasis Location .......................................................... 54
9.1.3. Health Outcom es/Qualit y of Life Measures .......................................................... 54
9.1.3.1. Itch Numeric Rat ing Scale .............................................................................. 54
9.1.3.2. Derm atology Life Qualit y Index..................................................................... 54
9.1.3.3. Children’s Dermatology  Life Quali ty Index.................................................... 55
9.1.3.4. Patient’s Gl obal Assessment of Di sease Severit y............................................ 55
9.1.4. Appropriateness of Assessments .......................................................................... 55
9.2. Adverse Events ............................................................................................................ 55
9.2.1. Serious Adverse Events ........................................................................................ 56
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 57
9.2.2. Adverse Events of Special Interest ....................................................................... 57
9.2.3. Com plaint Handling ............................................................................................. 58
9.3. Treatment of Overdose .................................................................................................58
9.4. Safety........................................................................................................................... 58
9.4.1. Physical Examinat ion........................................................................................... 58
9.4.2. Chest X -Ray and Tuberculosis Test ing.................................................................59
9.4.3. Electrocardiograms .............................................................................................. 60
I1F-MC-RHCD (b)Clinical Protocol Page 4
LY24398219.4.4. Bone Im aging ....................................................................................................... 61
9.4.5. Vital Signs ........................................................................................................... 61
9.4.6. Laboratory  Tests .................................................................................................. 61
9.4.7. Immunogenicit y................................................................................................... 61
9.4.8. Safety-Related Immune Markers .......................................................................... 62
9.4.9. Children’s Depression Rat ing Scale ..................................................................... 62
9.4.10. Columbia –Suicide Severi ty Rating Scale .............................................................. 62
9.4.11. Tanner Stage Scale ............................................................................................... 63
9.4.12. Safety Moni toring ................................................................................................ 63
9.5. Pharmacokinet ics......................................................................................................... 63
9.6. Pharmacodynamics ...................................................................................................... 64
9.7. Pharmacogeno mics ...................................................................................................... 64
9.8. Biomarkers ................................................................................................................... 64
9.9. Medical Resource Utilizat ion and Healt h Economics ................................................... 64
10. Statistical Considerations .................................................................................................. 65
10.1. Bone Im aging ............................................................................................................... 65
10.2. Sample Si ze Determinat ion.......................................................................................... 65
10.3. Popul ations for Analyses .............................................................................................. 65
10.4. Statistical Analyses ...................................................................................................... 66
10.4.1. General Statist ical Considerat ions........................................................................ 66
10.4.2.
Analysis Methods .................................................................................................67
10.4.2.1. Missing Data Imputation ................................................................................ 67
10.4.2.2. Nonresponder Imputation ............................................................................... 68
10.4.2.3. Last Observat ion Carried Forward .................................................................. 68
10.4.3. Adjustment for Mul tiple Com parisons .................................................................. 68
10.4.3.1. Subject Disposit ion......................................................................................... 68
10.4.3.2. Subject Characterist ics.................................................................................... 69
10.4.3.3. Concomitant Therapy ..................................................................................... 69
10.4.3.4. Treatment Compliance .................................................................................... 69
10.4.4. Efficacy Analyses ................................................................................................ 69
10.4.4.1. Co-Primary Analyses ...................................................................................... 69
10.4.4.2. Major Secondary  Analyses ............................................................................. 69
10.4.4.3. Other Secondary  Analyses .............................................................................. 70
10.4.5. Safety Analyses .................................................................................................... 71
10.4.5.1. Adverse Events ............................................................................................... 72
10.4.5.2. Clinical Laboratory  Tests ................................................................................ 72
10.4.5.3. Vital Signs, Physical Findings, and Other Safet y 
Evaluat ions..................................................................................................... 73
I1F-MC-RHCD (b)Clinical Protocol Page 5
LY243982110.4.6. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 73
10.4.7. Other Analyses ..................................................................................................... 74
10.4.7 .1. Health Outcom es/Qualit y of Life Measures .................................................... 74
10.4.7.2. Subgroup Analyses ......................................................................................... 74
10.4.8. Interim Analyses .................................................................................................. 75
11. References ........................................................................................................................ 77
12. Appendices ....................................................................................................................... 79
I1F-MC-RHCD (b)Clinical Protocol Page 6
LY2439821List of Tables
Table Page
Table RHCD.1. Object ives and Endpo ints............................................................................... 27
Table RHCD.2. Treatment Regimens ...................................................................................... 43
Table RHCD.3. Efficacy Analyses .......................................................................................... 71
Table RHCD.4. Analyses of Healt h Outcom es Variables ........................................................ 74
I1F-MC-RHCD (b)Clinical Protocol Page 7
LY2439821List of Figures
Figure Page
Figure RHCD.1. Illustrati on of  study  design for Clinical Protocol I1F -MC-RHCD. .................. 31
I1F-MC-RHCD (b)Clinical Protocol Page 8
LY2439821List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 80
Appendix 2. Clinical Laboratory  Tests ............................................................................... 84
Appendix 3. Study  Governance Considerat ions.................................................................. 85
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 88
Appendix 5. Blood Pressure Levels for Children with Median Height by Age and 
Gender ........................................................................................................... 89
Appendix 6. Protocol  Amendment I1F -MC-RHCD(b) Summary:  Mult
icenter, 
Doubl e-Blind, Rando mized, Placebo -Controlled Study  to Eval uate 
Safety, Tolerabili tyand Efficacy of Ixekizumab in Patients from 6 to 
Less than 18 Years of Age with Moderate -to-Severe Plaque Psoriasis ............ 91
I1F-MC-RHCD (b)Clinical Protocol Page 9
LY24398211.Synopsis
Title of Study:
Multicent er, Double -Blind, Randomized, Placebo -Controlled Study to Evaluate Safety, Tolerability, and Efficacy of 
Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate -to-Severe Plaque Psoriasis 
Note that patients will be described as subjects throughout this document.  
Rationale:
There is an unmet medical need for effective and safe therapies for children and adolescents with 
moderate -to-severe plaque psoriasis ( Ps).  Ixekizumab has been approved for the treatment of adults with moderate -
to-severe plaque Psand psoriatic arthritis ( PsA)in a number of countries globally.  It has also been approved for 
adults with Pustular Ps and Erythrodermic Ps in Japan and is currentl y being studied in adults with axial 
spondyl oarthritis.  This study is part of the European Pediatric Investigation Plan (PIP) and United States of 
America (USA )Pediatric Study Plan, and it is intended to investigate the safety, efficacy ,and pharmacokine tics 
(PK)of ixekizumab in pediatric subject s(children and adolescents).  Protocol Addendum I1F-MC-RHCD (1) 
describes additional PKsampling for a subgroup of subjects ,which will be used to help define the PKof 
ixekizumab in pediatric subjects.  Protocol Addendum I1F-MC-RHCD (2) states that in countries where etanercept is 
approved for severe pediatric plaque Ps treatment only (emerging markets and European countries) ,subjects may be 
randomized to etanercept.  Protocol Addendum I1F-MC -RHCD (2)contains an active -controlled reference group 
(etanercept) during the Double -Blind Treatment Induction Period (Period 2) .  Additionally, subjects from European 
Union (EU)countries who meet the response criterion (defined as static Physician’s Global Asse ssment [ sPGA ]
[0,1]) at Week 60 will be re -randomized to ixekizumab or placebo (1:1 ratio) during a 48 -Week Double -Blind, 
Randomized Withdrawal Period during Period 4.
Objective s/Endpoints:
Objectives Endpoints
Co-Primary
to assess whether ixekizumab Q4W is superior to placebo 
at Week 12 (Visit 7) in the treatment of pediatric subjects 
(children and adolescents) with moderate -to-severe 
plaque psoriasis as measured by PASI 75 and by sPGA 
(0,1)proportion of subjects achieving PASI 75 at 
Week 12
proportion of subjects achieving sPGA (0,1) 
at Week 12
Gated Secondary
to assess whether ixekizumab Q4W is superior to placebo 
as measured by:
PASI 90
sPGA (0)
PASI 100 
Itch NRS
PASI 75  
sPGA (0,1)proportion of subjects achieving PASI 90 at 
Week 12
proportion of subjects achieving sPGA (0) 
at Week 12
proportion of subjects achieving PASI 100 
at Week 12
Proportio n of subjects with an improvement 
of 4 in Itch NRS at Week 12 for subjects 
who had a baseline Itch NRS 4
proportion of subjects achieving PASI 75 at 
Week 2
proportion of subjects achieving sPGA (0,1) 
at Week 2
I1F-MC-RHCD (b)Clinical Protocol Page 10
LY2439821Objectives Endpoints
Other Secondary
to assess whether ixekizumab Q4W is superior to placeboThe following endpoints will be assessed at Week 12 
and at each postbaseline visit during the Double -
Blind Treatment Period:  
proportion of subjects achieving PASI 50, 
PASI 75, PASI 90, and PASI 100
proportion of subjects achieving sPGA (0,1) 
and sPGA (0)
change from baseline in itching severity 
(Itch NRS) score
CDLQI/DLQI (0,1) 
change from baseline in NAPSI, PSSI, 
and/o r PPASI score in case of nail, scalp, or 
hand/feet involvement
to summarize the efficacy of ixekizumab Q4W at 
Week 24 (Visit 10) and Week 48 (Visit 16) as measured 
by:
PASI 75
sPGA (0,1)
PASI 90 
sPGA (0)
PASI 100 The following endpoints will be assessed:
proportion of subjects achieving PASI 75 at 
Weeks 24 and 48
proportion of subjects achieving sPGA (0,1) 
at Weeks 24 and 48
proportio n of subjects achieving PASI 90 at 
Weeks 24 and 48
proportion of subjects achieving sPGA (0) 
at Weeks 24 and 48
proportion of subjects achieving PASI 100 
at Weeks 24 and 48
to evaluate the potential development of anti -ixekizumab 
antibodies and its impact on subject efficacy of 
IxekizumabPASI 75 and sPGA(0,1) at Week 12 
correlated with treatment -emergent antidrug 
antibody titer (low, moderate, and high) and 
by NAb status
tomeasure ixekizumab exposure and characterize the 
pharmacokinetics of ixekizumab in pediatric subjectsserum trough concentrations of ixekizumab
to assess the relationship between exposure and efficacy 
and exposure and immunogenicitymodel parameters for the exposure -response 
relatio nship between ixekizumab serum 
trough concentrations and efficacy 
endpoints (e .g., sPGA, PASI) at Week 12
serum trough concentrations for ixekizumab 
antibody titer subgroups
to assess the safety of ixekizumab to evaluate the safety of ixekizumab, 
including but not limited to infections; 
injection -site reactions; B -, T-, and NK -cell 
levels; WBC count; RBC count; and 
laborato ry values (hematology and 
chemistry  [including ALT and AST]) during 
the course of the study
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; BMI =body mass index; 
CDLQI = Children’s Dermatology Life Quality Index; DLQI = Dermatology Life Quality Index; 
Nab =neutralizing anti drugantibody; NAPSI = Nail Psoriasis Severity Index; NK = natural killer; 
NRS = numeric rating scale; PASI =Psoriasis Area and Severity Index; PASI 50 = at least a 50% improvement 
from baseline in PASI score; PASI 75= at least a 75% improvement from baseline in PASI score; PASI 90 = at 
least a 90% improvement from baseline in PASI score; PASI 100 = a 100% improvement from baseline in PASI
score; PPASI =Palmoplantar Psoriasis Severity Index; PSSI = Psoriasis Severity Index; Q4W = ever y 4 weeks; 
RBC =red blood cell; sP GA = static Physician ’sGlobal Assessment; WBC = white blood cell.
I1F-MC-RHCD (b)Clinical Protocol Page 11
LY2439821Summary of Study Design:
Study I1F-MC -RHCD is a Phase 3, multicenter, double -blind, randomized, placebo -controlled study examining the 
effects of ixekizumab versus placebo in subject s from 6 to <18 y ears of age with moderate -to-severe plaque Ps
(Psoriasis Area and Severity Index [ PASI ] score ≥12, sPGA ≥3, and body surface area [BSA ]≥10% at screening 
and baseline ).There is an active -controlled (etanercept) portion of the study design detailed in Protocol 
Addendum I1F-MC -RHCD (2).  
Treatment Group s and Duration:   
Subjects will receive placebo or ixekizumab during the Double -Blind Treatment Period(Inductio n Period) (Week 0 
to Week 12) and open -label ixekizumab during the Maintenance Period (Week 12to Week 60) and Extension Period 
(Week 60to Week 108) .  The selected ixekizumab doses are: 1) 80 mg every 4 weeks ( Q4W )(with a starting dose 
of 160 mg) for subjects >50 kg; 2) 40 mg Q4W (with a starting dose of 80 mg) for subjects 25 to 50 kg ;and 
3)
20mg Q4W (with a starting dose of 40 mg) for subjects <25 kg.
Number of Subject s:
Approximately 195 subjects will be randomized to the study .  Approximately 165 subjects will be randomized in a 
2:1 ratio to receive ixekizumab (110 subjects) or placebo (55 subjects) during the Double -Blind Treatment Period.  
Approximately 30 subjects in countries where etanercept is approved for severe pediatri cplaque Ps treatment only 
(emerging markets and European countries) will receive etanercept during the Double -Blind Treatment Period as
described in Protocol Addendum I1F -MC-RHCD(2).   
Statistical Analysis:
Continuous data will be summari zed in terms of t he mean, standard deviation, minimum, maximum, median, and 
number of observations.  Categorical data will be summari zed as frequency counts and percentages.  Comparisons 
between ixekizumab and placebo will be performed for all analyses in the Double -Blind Treatment Induction Period 
(Period 2).  Change from baseline will be calculated as the visit value of interest minus the baseline value.
Efficacy Analyses:
Efficacy analyses will be conducted for the Double -Blind Treatment Induction Period (Period 2) and allixekizumab 
treatment period s.  The primary analysis will be based on the intent to treat (ITT ) Population for Period 2 , Induction.  
In addition, an analy sis of the Per-Protocol Population will be used to support the primary efficacy analysis.   
Treatmen tcomparisons in the proportion of subjects achieving at least a 75% improvement from baseline in PASI 
score (PASI 75)response and the proportion of subjects with sPGA (0,1) at We ek 12 will be analyzed using Fisher ’s
exact test.  
Pharmacokinetics /Pharmacodynamics :
The PKof ixekizumab in pediatric subjects will be determined using population PKmethods.  The exposure -
response relationship will be investigated between observed steady -state trough concentrations of ixekizumab and 
clinically important efficacy measures ( e.g., sPGA and PASI endpoints) .
I1F-MC-RHCD (b)Clinical Protocol Page 12
LY2439821Health Outcomes:
The following health outcomes/quality of life scales will be used:  Itch NRS , DLQI , CDLQI, patient’s global 
assessment of disease severity.  
Safety Analyses: 
Safety of ixekizumab , including but not limited to infections ;injection -site reactions ; B-, T-, and natural killer 
(NK) -cell levels ;WBC count; RBC count; and laboratory values (hematology and chemistry [including ALT and 
AST ]) wil l be assess ed.
Safety a nalyses will be conducted for the Double -Blind Treatment Induction Period (Period 2) and for all 
ixekizumab treatment periods. Safety analysis will be based on the Safety  Population.  Safety will be assessed by 
summarizing and analyzing adverse events ( AEs);laboratory analytes ,including neutrophil counts ;Children’s 
Depression Rating Scale ( CDRS );Columbia -Suicide Severity Rating Scale ( C-SSRS );and vital signs.  The duration 
of treatment will also be summarized.
Vaccination Effects:
Immuni zation history will be recorded at baseline, and any unexpected outcomes or effects related to standard -of-
care vaccination will be summari zed.  
Interim Analys es:
Two interim analyses will be conducted.  The first interim analysis of PK, safety , and select efficacy data on all 
subjects will be conducted after approximately 15 subjects have completed to Week 12 in the 25 -to 50 -kg weight 
group. Asecond interim analysis will be performed at the time (that is, a cutoff date) the last subject completes 
Study Period 2, Induction (Week 12) or at the Early  Termination Visit.  Additional analyses and snapshots of study 
data may  be performed during and/or after completion of Period 3 and/or Period 4 to fulfill the need for regulatory 
interactions or publication purposes.
I1F-MC-RHCD (b)Clinical Protocol Page 13
LY24398212.Schedule of A ctivities
I1F-MC-RHCD (b)Clinical Protocol Page 23
LY2439821Schedule of Activities, Protocol I1F-MC-RHCD
Abbreviations:   AE = adverse event; AESI = adverse event of special interest; ALT = alanine aminotransferase ; AST = aspartate aminotransferase ; BP = blood 
pressure; BSA = body surface area; CDLQI = Children's Dermatology Life Quality Index; d =days; DLQI = Dermatology Life Quality Index ; 
ECG =electrocardiogram; ETV = Early Termination V isit; HBcAb+ = positive for anti -hepatitis B core antibody; HBsAb = hepatitis B surface antibody; 
HBV = hepatitis B virus; HCV = hepatitis C virus; HIV =human immunodeficiency virus; IgA = immunoglobulin A; IgG = immunoglobulin G; 
IgM =immunoglobulin M; IXE =ixekizumab (LY2439821); LV= last visit; NAPSI = Nail Psoriasis Severity Index; NK=natural killer; NRS = numeric 
rating scale; PASI = Psoriasis Area and Severity Index; PPASI = Palmoplantar Psoriasis Area and Severity Index; PPD =purified protein d erivative; 
PK=pharmacokinetics; PSSI = Psoriasis Scalp Severity Index; Q4W = every 4 weeks; SC = subcutaneous; sPGA = static Physician ’sGlobal Assessment; 
TB = tuberculosis; ULN = upper limit of normal; V = study visit; W = study week.
aThe parent or l egal guardian will sign the informed consent form, and the subject will sign the assent form prior to any study assessments, examinations, or 
procedures being performed.  An informed consent form should be signed by the subject when the legal age is reached as determined by the country 
regulations .  
bComplete medical history, including TB exposure .
cDemographics include recording the full date of birth, sex,and ethnicity. In countries where we are not allowed to collect the full date of birth, (day, month, 
and y ear) we will make country specific adjustments to collect only month and year. 
dOne complete physical examination (excluding pelvic, rectal, and breast examinations) will be performed at screening.  All physical examinations throughout 
the study  should include a symptom -directed physical as well as an examination of heart, lungs, and abdomen and a visual examination of the skin, including 
genitals .  
eHabits include recording of caffeine, alcohol, and tobacco consumption .  This assessme nt is only  required for subject s 12 years of age or older.  
fSubject s who test positive for latent TB at screening may be rescreened following appropriate treatment.  Additionally, subject s who do not qualify at 
screening under Exclusion Criterion [1 4] (active or recent infection) or Exclusion Criterion [ 16] (body temperature ≥38°C [100.5°F]) may be rescreened 1 
time.
gAt baseline (Week 0) , BP and pulse should be measured at least 30 minutes pre-and postinjection . BP and pulse should be measure dpre-and postinjection at 
the other visits .  
hInflammato ry bowel disease will be assessed as an AESI .  See Section 9.2.2 for a list of all AESIs.  
iThe study drug will be prepared by a trained clinical staff member who will be an unbli nded member.  Site staff will record information in the Study Drug 
Administ ration Log s, including the date, time ,and anatomical location of administration of study drug (for treatment compliance); syringe number; who 
prepared and administered the study drug ; and the reason if study drug was not fully administered.
jSubjects should remain under observation for at least 1 hour after dosing at Week 0 (Visit 2)
,Week 4 (Visit 4), Week 8 (Visit 6), Week 12 (Visit 7),and 
Week 16
(Visit 8) to monitor for safety.  For subsequent injection s during the study, and if no problems occurred with that injection, subjects will be observed 
for 15 minutes following injection .
I1F-MC-RHCD (b)Clinical Protocol Page 24
LY2439821kSubjects receiving ixekizumab 20 mg or 40 mg will receive 1 SC injection of ixekizumab at Week 0 (Visit 2) and 1 SC injection of ixekizumab Q4W at 
Weeks 4 and 8. Subjects receiving ixekizumab 80 mg will receive 2 SC injections of ixekizumab at Week 0 (Visit 2) and 1 SC injection of ixekizumab Q4W 
at Weeks 4 and 8.  
Subjects receiving placebo for ixekizumab 20 mg or 40 mg will receive 1 SC injection of placebo at Week 0 (Visit 2) and 1 SC injection of placebo Q4W at 
Weeks 4 and 8.  Subjects receiving placebo for ixekizumab 80 mg will receive 2 SC injections of placebo at Week 0 (Visit 2) and 1 SC injection of placebo 
Q4W at Weeks 4 and 8.  
lIf the subject has nail pso riasis, scalp psoriasis or palmoplantar psoriasis at baseline , then the NAPSI, PSSI or PPASI , respectively, will be administered at 
subsequent visits, as indicated in the Schedule of Activities .
mAt tanner stage score 5, the site does notneed to complete the scale with the subject any longer.
nA Self -Harm Follow -Up Form must be completed for each discrete event identified on the Self -Harm Supplement Form.
oQuantiFERON ®-TB Gold test is preferred.   For those subject s administered a PPD test,the subject will visit the site between 48 to 72 hours after PPD 
placement for the PPD read .  
pA chest x -ray will be taken at screening ,unless one has been obtained within the past 6 months (provided the x -ray and/o r report are available for revi ew). In 
Germany, a chest x -ray has to be performed within 6 months prior to signing informed consent indicating no evidence of TB.
qFor the Bone age imaging at Visit 2, it is acceptable if the test is performed at Visit 1. In case test is performed in t he last 6 months, it does not need to be 
repeated at Visit 2.
rSubjects must be supine for a minimum of 5 minutes before ECG collection and remain supine during ECG collection.  ECGs may b e obtained at additional 
times, when deemed clinically necessary.  
sSubject s who are HBcAb+, HBsAb+ ,and HBV DNA –at screening will be tested for HBsAb levels at baseline, at 12 -week intervals thereafter, and at the 
ETV, if applicable. Subject s who meet these criteria for HBsAb monitoring will be identified by the central lab oratory.  Subject s whose HBsAb levels are 
<200 mIU/mL at any postscreening visit will be tested for HBV DNA.   Any enrolled subject who is HBcAb+, regardless of HBsAb status or level, and who 
experiences elevated ALT or AST >3 times ULN must unde rgo HBV DNA testing.
tTo be performed for females of childbearing potential only (age s12 and older or younger subject s per investigator assessment of full sexual maturity). Serum 
pregnancy test will be done at Visit 1 only and will be performed centrall y.  Subject s will undergo urine pregnancy testing at the clinic on a monthly basis 
during scheduled visits through Week 108. Additional urine pregnancy testing can be performed at the investigator’s discretion.  Subject s determined to be 
pregnant will be discontinued from treatment and will no longer be administered study drug .
uWhere collection is allowed by local regulations.
vImmunogenicity samples may also be analyzed for ixekizumab serum concentration to facilitate in the interpretation of the imm unogenicity data.  In addition, 
a blood sample will be collected, when possible, for any subject who experiences a potential systemic allergic/hypersensitivity reaction during the study as 
judged by the investigator. At visits where study drug will be admin istered, immunogenicity samples will be collected prior to administration of study drug . 
Ideally ,samples will be taken at approximately the same time for each collection.
wAt visits where study drug will be administered, PK samples will be collected pri or to administration of study drug .
xAll subject s receiving study drug must enter into Period 5 and complete through Visit 802.  Subject s may  be followed beyond Visit 802 for continued 
monitoring of their neutrophil counts if determined by the Sponsor/investigator that additional monitoring is needed .  If a subject discontinues study drug
early , the subject will complete the ETV and then enter the Post -Treatment Follow -Up Period (Period 5).
yThis visit will only occur if a subject’s neutrophil counts have not re turned to the defined criteria.
I1F-MC-RHCD (b)Clinical Protocol Page 25
LY24398213.Introduction
3.1. Study Rationale
There i s an unmet m edical need for effect ive and safe therapies for children and adolescents with 
moderate -to-severe plaque Ps. Ixekizumab has been approved fo r the treatment of adults with 
moderate -to-severe plaque Ps and psoriatic arthrit is(PsA ) in a number of countries globally.  It 
hasalso been approved for adults with Pustu larPs and Ery throdermic Ps in Japan , and is
currently being studied in adults wit h axial spondyl oarthri tis.  This study  is part of the European 
PIP and USA Pediatric Study  Plan,and it i s intended to investigate the safet y, efficacy ,and PK 
of ixekizumab in pediatric subject s (children and adolescents).  This study  will assess specific 
response in the Pediatric Populat ion.  The risks and benefit s in the Pediatric Populat ion are 
expected to be similar to those in adults with plaque Ps.  There is no specific difference in the 
mechanism o f the disease; therefore , no difference in the safet y profile is expected between 
adults, adol escents, and children.  
Protocol Addendum I1F -MC-RHCD(1) describes addit ional PK sampling for a subgroup of 
subjects ,whichwillbe used to help define the PK of ixekizumab in pediatric subjects.  Protocol 
Addendum I1F -MC-RHCD(2) states that in countries where etanercept is approved for severe 
pediatric plaque Ps treatm ent only ( emerging markets and European countries) ,subjects may be 
rando mized to etanercept.  This addendum contains an act ive-controlled reference group 
(etanercept) during the Double -Blind Treatm entInduction Period (Peri od 2).  Addit ionally , 
subjects fro m EU coun tries who m eet the response criterion (defined as sPGA [0,1]) at Week 60 
will be re -rando mized to ixekizuma b or pl acebo (1:1 rati o) during a 48 -Week Double -Blind, 
Randomized Wit hdrawal Period during Period 4.
3.2. Background
Pediatric plaque Psaffects approximately 1% of children and ado lescents globally (Gelfandet al. 
2005; Napo litano et al . 2016) .  It is estimated that 3 5% to 50% of adults with psoriasis dev eloped 
their disease before 20years of age (De Jager et al . 2009).  In a report by Gelfand et al.(2005) , 
the prevalence of plaque Ps in children in the U nited Kingdo mwas 0.55% for those aged 0
to 
9 yearsand 1.37% for th oseaged 10 to 19 years.  Pediatric plaque Psis especially burdenso me 
because it often presents on the face and scalp, as well as other highly  visible areas.  Non bi ologic
topical therapies have been the mainstay  of treatment due to l ack of approved therapies for 
plaque Psin children.  Currently ,there are few systemic therapies for pediatric plaque Ps,and 
most have significant side effects or are not as effective as desi red(Bronckers et al. 2015).
Current ly,there is an unmet m edical need for effective and safe therapies for children and 
adolescents wi th moderate -to-severe psoriasis.   Both the PIP and Pediatric Study  Plan will focus 
on pedi atric subject s with moderate -to-severe plaque Ps fro m 6 to <18 y earsof age.
I1F-MC-RHCD (b)Clinical Protocol Page 26
LY24398213.3. Benefit/Risk Assessment
The m echanism  of action of ixekizumab is similar in adults and children ; therefore ,it is expected 
that the benefit /risk ratio of parti cipat ion in this study  will be the same in children as it is in 
studi es of  adul ts.  More informat ion about the known and expected benefit s, risks, serious 
adverse events (SAEs), and reasonably ant icipated adverse events (AEs) of ixekizumab 
(LY2439821) in adults are to be found in the Investigator’s Brochure (IB).
I1F-MC-RHCD (b)Clinical Protocol Page 27
LY24398214.Objectives and Endpoints
Table RHCD .1shows the objectives and endpo ints of t he study .
Table RHCD .1. Objectives and Endpoints
Objectives Endpoints
Co-Primary
to assess whether ixekizumab Q4W is superior to placebo 
at Week 12 (Visit 7) in the treatment of pediatric subjects 
(children and adolescents) with moderate -to-severe plaque 
psoriasis as measured by PASI 75 and by sPGA (0,1)proportion of subjects achieving PASI 75 at 
Week 12
proportion of subjects achieving sPGA (0,1) 
at Week 12
Gated Secondary
to assess whether ixekizumab Q4W is superior to placebo 
as measured by:
PASI 90
sPGA (0)
PASI 100
Itch NRS
PASI 75  
sPGA (0,1)proportion of subjects achieving PASI 90 at 
Week 12
proportion of subjects achieving sPGA (0) at 
Week 12
proportion of subjects achieving PASI 100 at 
Week 12
improvement ≥4 for subjects who had a 
baseline Itch NRS score ≥4
proportion of subjects achieving PASI 75 at 
Week 2
proportion of subjects achieving sPGA (0,1) 
at Week 2
Other Secondary
to assess whether ixekizumab Q4W is superior to placeboThe followin g endpoints will be assessed at Week 12 
and at each postbaseline visit during the Double -Blind 
Treatment Period:  
proportion of subjects achieving PASI 50, 
PASI 75, PASI 90, and PASI 100
proportion of subjects achieving sPGA (0,1) 
and sPGA (0)
change from baseline in itching severity (Itch 
NRS) score
proportion of subjects achieving 
CDLQI/DLQI (0,1)
change from baseline in NAPSI, PSSI ,and/o r 
PPASI score in case of nail, scalp, or 
hand/feet involvement
to summarize the efficacy of ixekizumab Q4W at Week 24 
(Visit 10) and Week 48 (Visit 16) as measured by:
PASI 75
sPGA (0,1)
PASI 90 
sPGA (0)
PASI 100 The following endpoints will be assessed:
proportion of subjects achieving PASI 75 at 
Weeks 24 and 48
proportion of subjects achieving sPGA (0,1) 
at Weeks 24 and 48
proportion of subjects achieving PASI 90 at 
Weeks 24 and 48
proportion of subjects achieving sPGA (0) at 
Weeks 24 and 48
proportion of subjects achieving PASI 100 at 
Weeks 24 and 48
to evaluate the potential development of anti -ixekizumab 
antibodi es and its impact on subject efficacy of 
IxekizumabPASI 75 and sPGA(0,1) at Week 12 
correlated with treatment -emergent antidrug 
antibody titer (low, moderate ,and high) and 
I1F-MC-RHCD (b)Clinical Protocol Page 28
LY2439821Objectives Endpoints
by NAb status
to measure ixekizumab exposure and characterize the 
pharmacokinetics of ixekizumab in pediatric subjectsserum trough concentrations of ixekizumab
to assess the relationship between exposure and efficacy 
and exposure and immunogenicitymodel parameters for the exposure -response 
relatio nship between ixekizumab serum 
trough concentrations and efficacy endpoints 
(e.g., sPGA, PASI) at Week 12
serum trough concentrations for ixekizumab 
antibody titer subgroups
to assess the safety of ixekizumab to evaluate the safety of ixekizumab, 
including but not lim ited to infections ;
injection -site reactions ; B-, T- , and NK -cell 
levels ;WBC count; RBC count; and 
laborato ry values (hematology and chemistry 
[including ALT and AST]) during the course 
of the study
Tertiary/Exploratory
to demonstrate normal growth and pubertal progression in 
children treated with ixekizumab during the course of the 
studyweight, height, and BMI data will be merged 
to the Centers for Disease Control and
Preventio n standard growth data by age and 
gender to compare subjects’ growth wit h 
normal values
shift table for tanner stage from maximum 
baseline to maximum postbaseline by gender
to evaluate the genital involvement of the subjects per the 
questionnaire Binary Questions on Psoriasis Locationproportion of subjects achieving no psoriasis 
presence in each psoriasis location
to evaluate the patient’s global assessment of disease 
severityproportion of subjects achieving patient’s 
global assessment of disease severity 0 or 1
to evaluate the effect of ixekizumab on maintenance of 
efficacy and health outcomes during the open -label 
maintenance period and extension period.proportion of subjects achieving PASI 90 
proportion of subjects achieving sPGA (0) 
proportion of subjects achieving PASI 100 
proportion of subjects achieving PAS I 75
proportion of subjects achieving sPGA (0,1) 
improvement ≥4 for subjects who had a 
baseline Itch NRS score ≥4
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; BMI = body mass index; 
CDLQI = Children’s Dermatology Life Quality Index; DLQI = Dermatology Life Quality Index; 
Nab =neutralizing anti drugantibody; NAPSI = Nail Psoriasis Severity Index; NK = natural killer; 
NRS = numeric rating scale; PASI = Psoriasis Area and Severity Index ; PASI 50 = at least a 50% improvement 
from baseline in PASI score; PASI 75 = at least a 75% improvement from baseline in PASI score; PASI 90 = at 
least a 90% improvement from baseline in PASI score; PASI 100 = a 100% improvement from baseline in PASI
score; PPASI = Palmoplantar Psoriasis Severity Index; PSSI = Psoriasis Severity Index; Q4W = ever y 4 weeks; 
RBC = red blood cell; sPGA = static Physician ’sGlobal Assessment; WBC = white blood cell.
I1F-MC-RHCD (b)Clinical Protocol Page 29
LY24398215.Study  Design
5.1. Overall Design
Study  I1F-MC-RHCD (RHCD) i s a Phase 3, mult icenter, double -blind, randomized, 
placebo -controlled study  examining the effects of ixekizumab versus placebo in subject s from 
6to <18 y ears of age with moderate -to-severe plaque Ps(PASI score ≥12, sPGA ≥3, andBSA 
≥10% at screening and baseline) .  There i s an act ive-controlled (etanercept) reference arm 
porti on of  the study  design detailed in Protocol Addendum I1F -MC-RHCD(2).  
The study  consists of 5 periods:
Period 1:  Screening Period (Visit 1) will assess subject eligibilit y and will 
occur approximately 7 to 30 days before Period 2 , Induct ion(baseline; Week 0; 
Visit2).
Period 2:  Double -Blind Treatment Period (Inducti on Period) will occur from Week 0 
(baseline; Visit 2) to Week 12(Visit 7) com paring ixek izumab withplacebo in a doubl e -
blind fashion.  Protocol Addendum  I1F-MC-RHCD(2) describes etanercept as a reference
control  group for countri es where etanercept is approved for treatm ent of chroni c severe 
plaque psori asis in children and adolescents fro m the age of 6 y ears who are inadequately 
controlled by, or are intolerant to, other systemic therapies or phototherapies.
Period 3:  48-Week Open -Label Maintenance Period will occur fro m Week 12
(Visit 7) to Week 60 (Visit 19).  Subjects rando mized to the ixekizumab group during 
Period 2, Induction will maintain the dose received during the previous period.   Subjects 
rando mized to placebo during Period 2 , Induction will receive ixekizumab at doses of 20, 
40, or 80 mg based on weight .  As part of Protocol Addendum  I1F-MC-RHCD (2), 
subjects randomized to etanercept during the Double -Blind Treatm ent Peri od will begin 
treatm ent wi th ixekizumab after an 8 -week washout period (to avoid ,for safet y reasons ,
increased risk wit h concurrent etanercept and ixekizumab e xposures).  
Period 4:  Extension Period will occur from Week 60(Visit 19) to Week 108 
(Visit 31).  Subjects will cont inue with open -label treatment of the ixekizumab 
dose received during the previous period (Peri od 3) .  Protocol Addendum 
I1F-MC-RHCD(2) d
escribes the 48-week Doubl e -Blind Rando mized Wit hdrawal 
Period for subj ects from EU countri eswho meet response criteria during the 
Maintenance Period (defined as sPGA [0,1]).  Subjects who enter the Double -
Blind Rando mized Wit hdrawal Period will be re -randomized to ixekizumab or 
placebo (1:1 rati o) at Week 60 (Visit 19).  
Period 5:  Post -Treatment Follow -Up Period is for safet y monitoring after 
treatm ent discont inuat ion for any  subject receiving at least 1 dose of study  drug .  
This period occurs from the last treatment period visit or Early Terminat ion Visit 
(ETV) for up to 24 weeks fo llowing that vi sit.
I1F-MC-RHCD (b)Clinical Protocol Page 30
LY2439821Figure RHCD. 1illustrates the study  design for the main study . Protocol Addendum 
I1F-MC-RHCD(2) contains the study  design figure describing e tanercept dosing and the 
Doubl e-Blind Rando mized Wit hdrawal Period.  Appendix 3 contains the study  governance 
considerations.
I1F-MC-RHCD(b) Clinical Protocol Page 31
LY2439821Abbreviations:  IXE = ixekizumab (LY2439821); LV = date of last visit; PK = pharmacokinetic; Q4W = every 4 weeks; 
SC=subcutaneous; V = visit; W =week.
Footnotes on following page.
Figure RHCD. 1. Illustration of study design for Clinical Protocol I1F -MC-RHCD.

I1F-MC-RHCD (b)Clinical Protocol Page 32
LY2439821Illustration of study design for Clinical Protocol I1F -MC -RHCD
aSubject s will be randomized to eith er ixekizumab or placebo in a 2:1 ratio. 
bSubjects receiving ixekizumab 20 mg or 40 mg will receive 1 SC injection of ixekizumab at Week 0 (Visit 2) and 1 SC injection of ixekizumab Q4W at 
Weeks 4 and 8.  Subjects receiving ixekizumab 80 mg will receive 2 SC injections of ixekizumab at Week 0 (Visit 2) and 1 SC injection of ixekizumab Q4W 
at Weeks 4 and 8.  
Subjects receiving placebo for ixekizumab 20 mg or 40 mg will receive 1 SC injection of placebo at Week 0 (Visit 2) and 1 SC injection of placebo Q4W at 
Weeks 4 and 8.  Subjects receiving placebo for ixekizumab 80 mg will receive 2 SC injections of placebo at Week 0 (Visit 2) a nd 1 SC injection of placebo 
Q4W at Weeks 4 and 8.  
cImmunogenicity and time -matched PK sample collection will occur as detailed in the Schedule of Activities (Section 2).
dSubjects randomized to ixek izumab during Period 2 , Induction will receive 1 SC injection of ixekizumab and 1 SC injection of placebo at Week 12.  Subjects 
randomized to the placebo group during Period 2 , Inductio
nwill be assigned to receive ixekizumab at doses of 20, 40, or 80 mg b ased on weight.  Subjects 
assigned to 20 mg will receive a starting dose of 40 mg , subjects assigned to 40 mg will receive a starting dose of 80 mg ,and s ubjects assigned to 80 mg will 
receive a starting dose of 160 mg.  All subjects will receive 2 SC inje ctions of ixekizumab at Week 12 and 1 SC injection of ixekizumab Q4W at Week 16 and 
thereafter.  Treatment with ixekizumab is weight based.  I fa subject changes weight category during the study, after completing the double blind treatment 
period (inductio n), the dose will be adjusted accordingly.
eAll subjects receiving study drug must enter into Period 5 and complete through Visit 802.  Subjects may be followed upbeyond Visit 802 for continued 
monitoring of their neutrophil count if determined by the Sponsor/investigator that additional monitoring is needed.
fAt V isit 2, randomization will occur based on the following weight groups:  1 ) <25 kg:  randomization to ixekizumab 20 mg, receiving a starting dose of 
40mg; 2 ) 25kg to 50 kg:  randomization to i xekizumab 40 mg, receiving a starting dose of 80 mg; and 3) >50 kg:  randomization to 80 mg, receiving a 
starting dose of 160 mg.  A staggered approach to enrol lment by weight group will be implemented with subject s 12 y ears of age or older and >50 kg 
enrolling initially  to the study.  If no safety concern is identified a fter an initial safety analysis of the first12 weeks of treatment inthe first 15 subject s >50 kg, 
subject s will star t to enro ll in the 25 -to 50 -kg group.  Once data are obtained to W eek 12 for approximately 15 subject s in the 25 -to 50 -kg group, an interim 
analy sis of PK, safety, and efficacy data in all subject s in the study  at that point will be performed to confirm doses for the remaining subject s in the study .  
Once confirmed, all weight groups will be open for enrol lment .
I1F-MC-RHCD (b)Clinical Protocol Page 33
LY24398215.1.1. Screening Period (Period 1)
The durati on of  the Screening Period is between approximately  7 and 30 day s and consists of 
1visit (Visit 1) to assess subject eligibilit y.  Subject s who have a PPD placed as part of their TB 
testing will have a second visit during this period to have PPD read.  The parent or legal guardian 
will sign the inform ed consent form  (ICF) ,and the subject will sign the assent form prior to any  
study  assessme nts, examinat ions, or procedures being performed.
All inclusio n and exclusion criteria are provided in Section 6.1and 6.2, respectively.  Screening 
procedures will be performed according to the Schedule of Act ivities (Section 2).  At Vi sit1, 
tubercul osis (TB) testing will be performed by one of the following methods:  
1)QuantiFERON ®-TB Gol d or 2) purified protein derivat ive (PPD) skin test (Secti on8.1.1 ).  
Subject s who are administered a PPD test at Visit 1 will visit the site between 48to 72 hours 
after PPD pl acement for the PPD to be read.   Subject s who are assessed as having latent TB at 
screening may be rescreened fo llowing appropri ate treatm ent as described in Section 9.4.2 .
Addit ionally , 
subjects who do not qualify at screening under Exclusio n Cri teria [28] or [29] may 
be rescreened (1 time) at least 4 weeks after documented resolut ion of symptoms. A serum 
pregnancy test, as applicable, will also be done at Visit 1 .
5.1.2. 12-Week Double -Blind Treatment Induction Period (Period 2)
The Induct ionPeriod (Peri od 2) will be a Doubl e-Blind Treatment Period that will occur fro m 
Week 0 (baseline; Visit 2) to Week 12(Visit 7).  Dosing will be as fo llows:  subject s >50 kg will 
receive a starting dose of 160 mg, then 80 mg every 4 weeks ( Q4W )thereafter; subject s 25 to 
50kg will receive a starting dose of 80 mg, then 40 mg Q4W thereafter; subject s <25 kg will 
receive a starti ng dose of 4
0 mg, then 20 m g Q4W thereafter.  E valuat ion of the co-primary 
endpo ints will occur at Week 12.  
At Week 0 (baseline; Visit 2), routine safet y assessments, laboratory  tests, health outcomes
assessments, and clinical efficacy assessments will b e perform ed on eligible subject s according 
to the Schedule of Act ivities (Section 2).
Treatment assignment is discussed in Sect ion 7.2.
Blinded dosing will occur at 4-week intervals throughout Period 2 , Induction .  See Secti on 7.1
and Table RHCD .
2for a full description o f all dosing regimens.  Subjects >50 kg will be 
administered 2 subcutaneous (SC) inject ions of ixekizumab or placebo at Week 0.  S ubjects 25to 
50 kg and <25 kg will receive 1 SC inject ion of i xekizumab or pl acebo at Week 0.   All subject s
will be administered 1 SC inject ion of ixekizumab or placebo Q4W at Week 4and Week 8,
regardl ess of theirassigned dos age regimen .  
The study  drug will be prepared by  unblinded study  site personnel . All doses will be 
administered on -site.
Subject s should remain under observat ion for at least 1 hour after dosing at Week 0 (Visit 2) 
Week 4 (Visit 4), Week 8 (Vi sit6), Week 12 (Visit 7), and Week 16 (Vi sit8) to monitor for 
I1F-MC-RHCD (b)Clinical Protocol Page 34
LY2439821safet y.  Following the first injection and if no problems occur with that inject ion, subjects will be 
observed for 15 minutes following inject ionat all other study  visits.
Female subjects of childbearing potential (age 12 and olderor younger subject s per investigator 
assessment of full sexual maturit y)will undergo a urine pregnancy test at the clinic on a m onthly 
basis during scheduled visits through Week 108.  Addit ional urine pregnancy test ing maybe 
perform ed at the invest igator’s discret ion.  Subject s determined to be pregnant will be 
discontinued fro m treatment and will no longer be administered 
study drug (see Section 8.1).
Subject s who discont inue the study for any reason during this period will stop treatment and 
continue to the ETV prior to entering the Post -Treatment Follow -Up Peri od (Peri od 5).
5.1.3. 48-Week Open -Label Maintenance Period (Period 3)
Subject s will init iate the Maintenance Period as follows:  
Subjects rando mized to the ixekizumab group during Period 2 , Induction will maintain 
the dose received during the previous period .  In addit ion, subjects will also receive 1 
placebo inject ion at Week 12 to m aintain the blind.
Subject s rando mized to the placebo group during Period 2 , Induction will be assigned to 
receive ixekizumab based on weight. Table RHCD .2provides details on the init ial and 
subsequent doses. 
If asubject change sweight category  following the Doubl e-Blind Treatm ent Peri od, the 
ixekizumab dose associ ated wi th that wei ght will be administered.  This may  happen at 
any time during the Maintenance Period.
For EU countries, please refer to Protocol Addendum RHCD (2).
5.1.4. 48
-Week Extension Period (Period 4)
Subject s will cont inue wit h open -label treatment of the ixekizumab dose received during 
the previous period (Peri od 3) and will receive an inject ion every  Q4W through Week 
104(Visit 30). Subjects will receive the ixekizumab dose according to weight, which 
will be reassessed during this peri od.  If a subject changes weight category , the 
ixekizumab dose associated with the most current weight will be administered.  This may  
happen at any  time during the Extension Pe riod.
For EU countries, please refer to Protocol Addendum RHCD (2).
5.1.5. Post -Treatment Follow -Up Period (Period 5
)
All subject s receiving study  drug , including those who discont inue the study, will be monitored 
at approximately 4 and 12 weeks after the date of their final inject ion of study  drug to monitor 
clinical safet y, including neutrophil levels.  If a subject ’s neutrophil count is ≥1500 cells/ L or 
greater than or equal to the subject 's baseline neutrophil count at 12 weeks fo llowing the l ast 
inject ion of ixekizumab, the subject ’s participat ion in the study  will be considered complete. If 
the subject ’s neutrophil count remains <1500 cells/μL at 24 weeks after the last inject ion, the 
investi gator, in consultat ion with the Sponsor, will determine and be responsible for fo llow-up 
evaluat ions through appropriate healthcare options.
I1F-MC-RHCD (b)Clinical Protocol Page 35
LY2439821For subject s who completed or discont inued study  treatm ent and have entered the Post -
Treatment Follow -Up Peri od (Peri od 5), plaque Ps ther apy with another agent is allowed after an 
appropriate washout period , as determined appropriate by  the invest igator (see Section 7.7).
5.2. Number of P articipants
Approximately  195 subjects will be rando mized to the study .  Approximately  165 subjects will 
be randomized in a 2:1 ratio to receive ixekizumab (110 subjects) or placebo (55 subjects) during 
the Doubl e-Blind Treatment Period.  Approximately 30 subjects will receive etanercept during 
the Doubl e-Blind Treatment Period as described in Protocol Addendum  I1F-MC-RHCD(2).  
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2)for the last subject .
5.4. Scientific Rationale for Study Design
Study  RHCD includes 3 treatm ent periods: 1) a Double-Blind Treatm ent Induction Period 
(Peri od 2) ;
2)an Open-Label Maintenance Periodin which all subjects receive i xekizumab 
(Peri od 3) ;and3)an Open-Label Extensio n Period (Peri od 4) to determine the efficacy  and 
safet y of ixekizumab.  During the 12 -week blinded treatment period, ixekizumab Q4W is 
compared withplacebo Q4W, whereas during the Open-Label Maintenance Period, all subjects 
are treated with ixekizumab Q4W.  These period durations were chosen based on Phase 3 pivotal 
clinical studies condu cted in adul ts wi th moderate -to-severe plaque Ps.  The pl acebo -controlled
Doubl e-Blind Treatm ent Peri od is designed to minimize bias in the evaluat ion of ixekizumab in 
subjects wi th moderate -to-severe plaque Ps.  Subjects may still receive treatment in the form of 
the allowed conco mitant therapi es as described in the study  exclusio n criteria (Secti on 6.2) and 
the conc omitant therapy  section (Secti on 7.7).
The efficacy of ixekizumab in treating plaque Ps will  be measured by  the PASI and sPGA and 
scales, with the p rimary  efficacy  endpoint at Week 12.  These measures and the 12- week 
endpo int are in alignment with efficacy endpo ints for currently approved plaque Ps therapi es and 
with regul atory  guidance (EMEA [WWW] ).  The Open -Label  Maintenance Peri od and 
Extensio n Periodwill permit co llection of data for the assessment of maintenance of efficacy and 
long-term safet y data wi th ixekizumab.
The Post -Treatment Follow -Up Peri od (Peri od 5) is for safet y monitoring fo llowing the l ast 
treatm ent peri od and study  visit.
Study discontinuation criteria allow subjects to be di scontinued at any  time by investigator or 
subject decisio n if the subject i s receiving insufficient benefit fro m study  therapy  or requires
treatm ent wi th another therapeuti c agent that has been demo nstrated to be effective for treatment 
of plaque Ps(Secti on8.1.1 ).
Clinical studi esof plaque Psrequi re obj ective measurement of psoriasis disease activit y/severit y.  
The current gold standard for assessment of extensive psoriasis has been the PASI .The PASI is 
a measure of the average redness, thickness, and scaliness of th e lesions (each graded o n a 
I1F-MC-RHCD (b)Clinical Protocol Page 36
LY24398210-4scale), weighted by the area of invo lvement. Clinicians t ypically consider at least 75% 
improvement in disease to be a clinically meaningful improvement indicative of success.  
Although the PASI has been the most widely used measure, it does have a number of limitat ions, 
one of which is its poor sensit ivity to change for relat ively small  areas of involvement.  Another 
major limitat ion of the PASI is that it is not routinely used by clinicians and therefore is poorly 
understood by  both clinicians an d subjects .  Thus ,the sPGA was added as a co-primary measure .  
The sPGA measures the physician’s impressio n of the disease at a single point ; it is a 
well-recognized clinical tool  for assessing subject improvement .  The PASI and sPGA were also 
used as co -primary endpo intsin the ixekizumab Phase 3 studies in adult subjects with moderate -
to-severe plaque Ps.
5.5. Justification for Dose
The efficacy, safet y, and PK data fro m the Phase 2 and Phase 3 programs in adults with plaque
Pshave been used to guide the dose and dosing regimen for invest igation in pediatri csubject s 
with plaque Ps.Weight was ident ified as an important covariate factor on clearance and volume 
terms in the adult popul ation PK model. Therefore, the adult PK m odel and the adul t sPGA time 
course exposure -response model were used to simul ate the expected PK and PD responses across 
a range of ages and weights in pediatric subject s to support select ion of the weight categories, 
doses, and dosing frequency proposed in this study. The recommended doses have been selected 
to target exposures in pediatric subjects to be within the range of exposures observed in the 
Phase 3 adult studies with the 80 mg every  2 weeks and 80 m g Q4W doses ,which both had a 
positive benefit /risk rat io.
Simulations in pediatric subjects using the adult popul ation PK model and the adult sPGA t ime 
course m odel were conducted. The weight distribution in the 6 -to 18 -year-old popul ation was 
based on the Centers for Disease Control  and Prevent ion (CDC )current growth charts (CDC 
[WWW]) . In the PK model, the thigh was assumed as the inject ion site of drug administration
because this location resul ted in slight ly higher exposure than arm and abdo men sites of 
administration (bioavailabilit y estimates of 90% and 81%, respectively) and thus provi des the 
most conservat ive est imate of exposure .  
Results fro m the modeling and simulat ion support the fo llowing doses, dosing frequencies ,and 
weight categori es to be used in this study: 1) 80 mg Q4W (with a starting dose o f 160 m g) for 
subjects >50 kg; 2) 40 mg Q4W (with a starting dose of 80 mg) for subjects 25 to 50 kg and; 
3)
20mg Q4W (with a starting dose of 40 mg) for subjects <25 kg.
Two interim analys es are planned f or thi s study  that will include an assessment of PK, safet y,
and select efficacy data from the init ial subject s enrolled in this study  to confirm the predictions . 
If necessary, dosage adjust ments may be made for the rem ainder of the subject s based on this 
review (see Section10.4.8 for more details of the interim analysis).
I1F-MC-RHCD (b)Clinical Protocol Page 37
LY24398216.Study  Population
The study  popul ation will consist of m ale and femal e subject s from 6 to <18 years of age with 
moderate -to-severe plaque Ps(PASI score ≥12, sPGA ≥3,and BSA ≥10% at screening and 
baseline ).  
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Subject s are eligible to be included in the study  only  if they  meet all  of the f ollowing criteria at 
screening:
Type of Subject and Disease Characteristics
[1] have a diagnosis o f moderate -to-severe plaque -type psori asisfor at least 
6months pri or to baseline (Week 0; Visit 2), as determined by the invest igator
[
2]have PASI score ≥12, sPGA ≥3,and BSA involvement ≥10% at screening 
(Visit 1) and baseline (Week 0; Visit 2)
[
3]are candidates for phototherapy  or sy stemic treatment or considered by  the 
investi gator as not adequately  controlled by topi cal therapi es
Subject Characteristics
[
4]male and female subject s from 6 to <18 y ears of age at time of randomizat ion
[4a] male subjects agree to use a reliable method of birth control during the study
[4b] female subjects:
Parti cipants of  childbearing age or childbearing potential who are sexually act ive 
who test negative for pregnancy must be counseled and agree to use either 1 
highly  effect ive method of contraception or 2 acceptable methods of 
contraception combined for the duration of the study and for at least 12 weeks 
following the last dose of study  drug, or rem ain abstinent during the study  and for 
at least 12 weeks fo llowing the l ast dose of study  drug.
If the highly effect ive contraceptive methods ar e contraindicated or strictly declined by 
patient, acceptabl e birth control  methods m ay be consi dered. These m ay include 
combinat ion of both of the fo llowing methods:
Male or female condo m with spermicide
Cap, diaphragm, or sponge with spermicide
1. Highly effect ive methods of contraception (use 1 form):
a.combined oral contraceptive pill and mini -pill
b.NuvaRing®
I1F-MC-RHCD (b)Clinical Protocol Page 38
LY2439821c.implantable contraceptives
d.injectable contraceptives (such as Depo -Provera®)
e.intrauterine device (such as Mirena® and ParaGard®)
f.contraceptive patch —ONLY women <198 pounds or 90 kg
g.abstinence fro m sex
h.vasectomy —for men in clinical studies
2. Effect ive methods of contraception (use 2 forms combined)
male condo m with spermicide
female condo m with spermicide
diaphragm  with spermicide
cervical sponge
cervical cap with spermicide
Females who are not of childbearing potential include those who have undergone or who have:
female sterilization
hysterectomy
menopause
Müllerian agenesis (Mayer –Roki tansky –Küster–Hauser syndro me [also referred to as 
congenita l absence of the uterus and vagina])
[5] both the child or adolescent and a parent or legal guardian are able to 
understand and fully participate in the activit ies of the clinical study  and sign 
their assent and consent, respectively ,accordance to local g uidelines. 
[
6]all immunizat ions are up -to-date in agreement with current immunizat ion 
guidelines as noted by  country  specific pediatric authorities (e.g., the 
American Academy of Pediatrics) .  Note, subject s who are not up to date or 
have never b
een immu nized are not to be enrolled in the trial. 
6.2. Exclusion Criteria
Subject s will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening:
Medical Conditions
[7] have pustular, ery throdermic, and/or guttate forms of plaque Ps
[
8]subject s with drug -induced plaque Ps (e . g., a new onset of plaque Ps or an 
exacerbation of plaque Ps from beta -blockers, calcium channel blockers, or 
lithium)
[
9]have clinical and/or laboratory  evidence of untreated l atent or active TB
I1F-MC-RHCD (b)Clinical Protocol Page 39
LY2439821[10]have eviden ce of  or test posi tive for hepatit is B virus (HBV) by  testing 
positive for 1) hepatit is B surface ant igen (HBsAg+) or2) anti -hepati tis B 
core anti body  (HBcAb+) and are HBV DNA posit ive. (Note:  Subject s who 
are HBcAb+ and HBV DNA negat ive may be enrolled in the study . Subject s 
who meet these criteria at screening will be ident ified by the central laboratory  
and mo nitored during the study )
[11]have evidence of or test positive for hepatit is C virus (HCV).  A posit ive test 
for HCV i s defined as:  1) posit ive for hepatit is C ant ibody  and 2) posit ive via 
a confirmatory  test for HCV ( e
.g., HCV polymerase chain reaction)
[
12]have or had an infect ion typical  of an immunocompromised host and/or that 
occurs with increased incidence in an immunocompromised host ( including 
but not limited to Pneumocystis jiroveci pneum onia, histopl asmosis, or 
coccidio idomycosis) or have a known immunodeficiency
[13] have or had a herpes zoster or any  other clinically apparent varicella -zoster 
virus infect ion within 12 weeks of baseline (Week 0; Visit 2)
[
14]have any other active or recent infect ion, including chronic or localized
infect ions, within 4 weeks of baseline (Week 0; Visit 2) that, in the opinio n of 
the invest igator, would pose an unacceptable risk to the subject if participating 
in the study; these subject s may be rescreened (1 time) 4 or more weeks after 
docum ented resol ution of symptoms
[
15]have sepsis or risk of sepsis
[
16]have a body  temperature ≥38°C (100.5°F) at baseline (Week 0; Visit 2); these 
subject s may b e rescreened (1 time) ≥4 weeks after documented resolut ion of 
elevated tem perature
[
17]subject s with a docum ented history  of immune deficiency syndrome ( e .g., 
severe combined immunodeficiency  syndrom e, T-cell deficiency  syndrom es, 
B
-cell deficiency  syndromes, chronic granulo matous di sease)
[18] subject s with a known history  of malignancy ;lymphoproliferat ive disease, 
including lympho ma;or signs and symptom s suggestive of possible 
lymphoproliferat ive disease, such as lymphadenopathy and/or spleno megaly
unless rul ed out by  biopsy
[
19]history  of major immunol ogic react ion (such as serum sickness or 
anaphylactoi d reacti on) to an immunogl obulin G ‒containing agent (such as 
intravenous gamma globulin, a fusio n protein, or mo noclonal antibody )
[
20]has had any major surg ical procedure within 8 weeks prior to baseline 
(Week 0; Visi t 2) or will  require such during the study  that, in the opinio n of 
the invest igator in consultat ion with Lilly  or its designee, woul d pose an 
unacceptable risk to the subject
I1F-MC-RHCD (b)Clinical Protocol Page 40
LY2439821[21]prese nce of significant uncontrolled cerebrocardiovascular disorder (e.g., 
unstable arterial hypertensio n, moderate -to-severe [New York Heart 
Associ ation class III/IV] heart failure ,cerebrovascular accident) ;respi ratory , 
hepat ic, renal, gastrointest inal, endo crine, hematologic, or neurologic 
disorders ;or abnorm al laboratory  values at screening that, in the opinio n of 
the invest igator, pose an unacceptable risk to the subject if participating in the 
study  or of  interfering with the interpretation of data
[22] presence of significant uncontrolled neuropsychiatric disorder that, in the 
opinio n of the invest igator, pose s
an unacceptable risk to the subject if 
participat ing in the study or of interfering wit h the interpretation of data ;
recent history  of a sui cide attem pt (duri ng the 30 days prior to screening) ;or 
marked yes to C -SSRS question 4 or 5 on ideat ion or y es to sui cide behavio rs
[23] had a serious infect ion (e .g., pneumo nia, cellulit is);have been hospitalized ;
have received intravenous antibiot ics for an infection within 12 weeks prior to 
baseline (Week 0; Visit 2) ;had a serious bone or joint infect ion within 
24weeks prior to baseline ;have ever had an infectio n of an artificial jo int;or 
are immunocompro mised to an extent that participation in the study  woul d 
pose an unacceptable risk to the subject
[
24] have not had any immunizat ions ,or are not up to date on immunizat ions 
recommended by  country  specific Pedi atric gui dance
[25] females of childbearing potent ial, who are sexually  active and not on ei ther 
1highly effective form of contraception or 2 effective forms of contraception 
(see Section6.1. Incl usion Criteria 4b)
[26] females o f childbearing potential, who are pregnant or intending to beco me 
pregnant or are breastfeeding
[
27]have any other condit ion or lab oratory values that,in the opinio n of the 
investigator, preclude the subject from following and com pleting the protocol
[
28]have evidence of precocious pubert y at the time o f study  enrol lment
[
29]at screening, have a neutrophil count <1500 cells/μL (<1.50 x 103/L or 
<1.50 GI/L ), a lymphocyte count <800 cells/μL (<0.80 x 103/ L or 
<0.80 GI/L), or a platelet count <100,000 cells/μL (<100 x 103/ L or 
<100 GI/L)
[30] a t screening, have ALT or AST >2.5 times the upper limit of normal (ULN). 
(Note:  ALT and AST m ay be repeated once within a week if the init ial 
response exceeds this l imit, and the repeat value may  be accepted if it meets 
this criterion)
[
31] a t screening, have a total WBC count <3000 cells/μL (<3.00 x 103/L or 
<3.00 GI/L) ,hemoglobin <8.5 g/dL (85.0 g/L) for male subject s,and 
hemoglo bin <8.0 g/dL (80 g/L) for female subject s
I1F-MC-RHCD (b)Clinical Protocol Page 41
LY2439821Prior/Concomitant Therapy
[32]subjects previously  treated wi th etanercept
[
33]have used any therapeut ic agent targeted at reducing interleukin - 17
[34]have received other therapies wit hin the specified time frames prior to 
screening (see below) :
adalimumab and infliximab 60 days, abatacept 90 days, anakinra 7 days, 
or any  other bi ologic disease -modifying ant irheumati c drug 5half-lives 
systemic therapy  for plaque Ps and PsA (other than above, e .g., 
methotrexate , 
cyclo sporine )or phototherapy (e .g.,photochemotherapy  
[psoral en pl us ul traviolet A]) in the previous 4 weeks
any invest igational drugs in the previous 4 weeks or 5 half -lives, 
whichever i s longer
ultravio let-
Atherapy , ultraviolet-Btherapy , and topical treatments (except 
on face, scalp ,and genital area during screening) in the previous 4 weeks
[35] had a live vaccinat ion within 12 weeks prior to baseline (Week 0, Visit 2), 
intend to have a live vaccinat ion during the course of the study  or wi thin 
12weeks of complet ing treatment in this study , or have participated in a 
vaccine clinical study  within 12 weeks pri or to baseline.  Invest igators should 
review the vaccinat ion from Pediatric governance bodies n onlivevaccines 
intended to prevent infect ious di sease pri or to therapy . (Note:  killed/inact ive 
or subunit vaccines are expected to be safe; however, their efficacy wit h 
concomitant ixekizumab treatment is unknown)
[36] are not up to date on all vaccinat ions according to country -specific guidance 
provi ded by pediatric governing bodies (e.g., the American Academy of 
Pediatrics), or have not had any vaccinat ions.
[
38] i f participating at a site where PPD is administered (rather than 
QuantiFERON® -TBGold), 
had a vaccination wit h Bacillus Calmette -Guérin 
(BCG) wi thin 12 m onths pri or to base line (Week 0, Visit 2) or intend to have 
vaccination wit h BCG during the study  or wi thin 12 m onths of com pleting 
treatm ent in this study
Prior/Concurrent Clinical Study Experience
[39]are currently enrolled in any other clinical study  involving an invest igational 
product or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study
[40] have participated, within the last 30 days ,in a clinical study  involving an 
investigat ional product.  If the previous inves tigational  product has a long 
half-life, 4 weeks or 5 half -lives (whichever is longer) should have passed
I1F-MC-RHCD (b)Clinical Protocol Page 42
LY2439821[41]have previously completed or withdrawn fro m this study  or any  other study  
investigat ingixekizumab
Other Exclusions
[42] are study  site personnel direct ly affiliated with this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted
6.3. Lifestyle Restrictions
Not applicable.
6.4. Screen Failures
Individuals who do not m eet the cri teria for parti cipati on in this study  (screen failure) m ay be 
re-screened 1 time .  
Those who test posit ive for latent TB at screening or who have a 
docum ented history  of a posi tive TB test but nodocumented history  of at least 4 weeks of 
appropr iate latent TB treatment may be re -screened fo llowing appropri ate treatm ent,as described 
in Section 9.4.2 .  The interval between re -screenings should be at least 1 month.  Each time 
re-screening is performed, the individual must sign a new ICF and will be assigned a new 
ident ificat ion number.
I1F-MC-RHCD (b)Clinical Protocol Page 43
LY24398217.Treatment s
7.1. Treatments Administered
This study  involves a comparison of ixekizumab administered by SC inject ionwith placebo .  
The study  drug shoul d be at room  temperature when injected.  Possible injection sites include the 
abdo men, thi gh, and upper arm  (using the arm contralateral for blood samples for PK).  The 
inject ion site should preferably  not be in a psoriat ic lesion and shoul d be rotated to another area 
for subsequent doses at the sam e visi t.
Table RHCD .2shows the treatment regimens.
Table RHCD .2. Treatment Regimens
RegimenDose
Week 0Dose
Week 4 and Week 8Dose
Week 12Dose
Week 16 through 
Week 104
Ixekizumab 
>50 kg160 mg 
(administered as 2
80-mg SC injections) 80-mg Q4W SC 
injection80-mg SC injection + 
aplacebo injection at 
Week 1280-mg Q4W SC 
injection
Ixekizumab 
25-50 kg80-mg SC injection 40-mg Q4W SC 
injection40-mg SC injection + 
aplacebo injection at 
Week 1240-mg Q4W SC 
injection
Ixekizumab 
<25 kg40-mg SC injection 20-mg Q4W SC 
injection20-mg SC injection + 
aplacebo injection at 
Week 1220-mg Q4W SC 
injection
Placebo 
>50 kgPlacebo for ixekizumab 
160mg 
(administered as 
2placebo SC injections) Placebo for 
ixekizumab 80 -mg 
Q4W SC injection Starting ixekizumab 
dose: 160-mg 
(administered as 2 
80-mg SC injections)80-mg Q4W SC 
injection
Placebo 
25-50 kgPlacebo for ixekizumab 
80-mg SC injectionPlacebo for 
ixekizumab 40 -mg 
Q4W SC injection Starting ixekizumab 
dose: 80-mg 
(administered as 2 
40-mg SC injections)40-mg Q4W SC 
injection
Placebo 
<25 kgPlacebo for ixekizumab 
40-mg SC injection Placebo for 
ixekizumab 20 -mg 
Q4W SC injection Starting ixekizumab 
dose: 40-mg 
(administered as 2 
20-mg SC injections) 20-mg Q4W SC 
injection
Abbreviations:  Q4W = ever y 4 weeks; SC = subcutaneous.
The invest igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the study  drug to the subject or the subject’s 
caregiver
verifying that instructions are fo llowed properly
maintaining accurate records of study  drug dispensing and collect ion
I1F-MC-RHCD (b)Clinical Protocol Page 44
LY2439821at the end of the study ,returning all unused medication to Lilly or its designee, 
unless the Sponsor and sites have agreed that all unused medicat ion is to be 
destroy ed by  the si te, as all owed by l ocal law
7.1.1. Packaging and Label ing
Clinical study  materials will be labeled according to the country ’s regul atory  requi rements.
The study  drug will be supplied by the Sponsor in accordance with current good manufacturing 
practi ces.
Ixekizumab and placebo for ixekizumab (excipients only ) will  be supplied as an injectable 
solution in 1-mL, s ingle -dose, prefilled, disposable manual sy ringes wi th study -specific labels.  
Each syringe of ixekizumab is designed to deliver ixekizumab 80 mg.  
Starti ng dose at W eek 0:  Subjects requiring the starting dose of 160 mg (ixekizumab or placebo 
to match) w ill receive two80-mg SC inject ions.  Subjects requiring the starting doses of 80 mg 
and 40 mg (ixekizumab or placebo to match) will receive 1 SC inject ion.  
Starti ng dose at Week 12 for subjects who had been receiving placebo:  Subjects requiring the 
starting dose of 160 mg ixekizumab will receive two 80
-mg SC inject ions.  Subj ects requi ring 
the starting dose of 80 mg ixekizumab will receive two 40-mg SC inject ions.  Subjects requiring 
the starting dose of 40 mg ixekizumab will receive two 20-mg SC inject ions.  
Ongo ing injections:  Subject s requiring a lower dose of ixekizumab or placebo will have the dose 
prepared by  inject ing the contents of the 80 -mg syringe into an empty sterile vial, then 
withdrawing and administering the required volume with a disposable sy ringe (0.5 mL for 40 m g 
and 0.25 m L for 20 m g).  The sy ringes (and contents) containing either ixekizumab or matching 
placebo will  be visibly indist inguishable fro m each other.  
Syringes will be supplied in cartons, with the appropriate quantit y of syringes specific to the 
planned dispensing schedule of the study  drug .  Clinical study  materials will be labeled 
according to the country’s regulat ory requi rements.  All study  drug will be stored, inventoried, 
reconciled, and destroy ed according to applicable regulat ions.
7.2. Method of Treatment Assignment
Subject s who meet all enrollment criteria at Visi t 1 and Visi t 2will be rando mized in a 2:1 ratio 
to double -blind treatment with ixekizumab or placebo at Week 0 ( Visit 2).  Assignment to 
treatm ent groups will be determined by a computer
-generated random sequence using an 
interact ive web -response system (IWRS).  The IWRS will be used to assign cartons containing 
doubl e-blind study  drug to each subject .  Study  site personnel will confirm that they  have l ocated 
the correct carton by entering a confirmat ion number into the IWRS.
To achieve between -group com parabilit y for region , the randomization will be st ratified by  
region (Uni ted States/Canada, European countries , and the rest of the world ).
During the Maintenance and Extensio n periods , all subject s will receive open -label treatment 
with ixekizumab. 
I1F-MC-RHCD (b)Clinical Protocol Page 45
LY24398217.2.1. Selection and Timing of Doses
Subjects willberandomized to treatm ent and will receive their assigned study  drug as outlined in 
Secti ons7.1and 7.2.  
As often as possible, study  drug shoul d be administered at approximately  the same t ime of day at 
each visit .  For inject ions that are missed and not administered on the scheduled day of th e week, 
the missed dose should be administered within 5 days of the originally scheduled day.  Dates of 
subsequent study  visits shoul d not be m odified according to the delay of the injection of the 
missed scheduled dose.
The actual  time and si te of all dos e administrations will be recorded in the subject ’s case report 
form (CRF).
7.3. Blinding
The Doubl e-Blind Treatm entInduction Period (Peri od 2) is double- blind ed; subjects and study  
site personnel will be blinded to treatment assignments.
To preserve the blinding of the study , a minimum number of Lilly  personnel  will see the 
rando mizat ion table and treatment assignments before the study  is complete.
Emergency  unblinding for AEs m ay be perform ed through the IWRS , which m ay supplement or 
take the place of em ergency  codes generated by  a com puter drug -labeling system.  This option 
may be used ONLY if the subject ’swell-being requi res knowl edge of subject ’s treatm ent 
assignment.  All actionsresul ting in an unblinding event willberecorded and reported by  the 
IWRS .
If an invest igator, study  site personnel  performing assessments, or subject is accidentally 
unblinded, the subject must be discontinued from the study.  If there are ethical reasons for the
subject to remain in the study , the invest igator must obtain specific approval fro m a Lilly  clinical 
research physician (CRP) or designated clinical research scient ist (CRS )for the subject to 
continue in the study .
In case of an emergency , the invest igator has the sole responsibilit y for determining whether
unblinding of a subject ’s treatment assignment is warranted.  Subject safet y must always be the 
first considerati on in making such a determinat ion.  If the invest igator decides that unblinding is 
warranted, the invest igator should make every effo rt to con tact the Lilly -designated CRP/CRS 
prior to unblinding a subject ’s treatment assignment ,unless this could delay emergency 
treatm ent of the subject .  If a subject ’s treatm ent assi gnment i s unblinded, Lilly  must be notified 
immediately .
7.4. Dosage Modification
During the Double -Blind Treatm entInduction Period (Peri od 2) , subjects will receive treatment 
regimen based on their baseline weight category  and are not allowed to modify  the treatm ent 
regimen during this treatment period.  At each visit following the Double-Blind Treatm ent
Period, the subject’s ixekizumab dose will  be modified if the subject changes weight categories . 
I1F-MC-RHCD (b)Clinical Protocol Page 46
LY2439821The first interim analysis will confi rm whether exposures are as expected and whether exposure -
response is similar in pediatric subjects to response in adults. Review of the data at this interim 
could lead to dosing regimen modificati on for some or all  ongoing and future subjects based on 
the findings . Any changes to dosing regimens recommended by  the DMC will be reviewed by  
the Lilly Sen ior Management Designee who will determine whether changes will be 
implemented.
The interim analyses are described in further detail in Sect ion 10.4.8 .
7.5. Preparation/Handling/Storage/Accountability
Study  drug will be supplied by Lilly or its representative in accordance with current good 
manufacturing practices and will be supplied wit h lot numbers, expir ationdates, and certificates 
of analysis, as applicable.
The study  drug shoul d be stored at 2°C to 8°C (36°F to 46°F) in its original carton to protect it 
from light.  Study  drug should not be frozen or shaken .  Sites will be requi red to m onitor 
temperature of the on-site storage condit ions of the study  drug .  
7.6. Treatment Compliance
Every  attem pt will be m ade to sel ect subjects who have the abilit y to understand and co mply 
with instructi ons.  The invest igator is responsible for discussing methods with the subject and 
caregiver before randomization to ensure high treatment compliance.  
Throughout the study , site personnel  will record inform ation in theStudy  Drug Administrati on 
Logs, including the date, time, and anatomical lo cation of  administrati on of  study  drug (for 
treatm ent com pliance) ;syringe number ;who prepared and administered the study  drug ;and the 
reason if study  drug was not fully administered.
Subject compliance wi th the study  drug will be assessed at each visit.  Compliance will be 
assessed by the number of inject ions needed versus the number of inject ions administered to the 
subject s.  Devi ation(s) from the prescribed dosage regimen should be recorded in the CRF.
7.7. Concomitant Therapy
Previous plaque Ps therapi es and all  concomi tant medicat ion taken during the study  must be
recorded in the electroni c CRF (eCRF) .  Treatm ent wi th plaque Ps therapi es during the study  is 
permitted only as outlined in the inclusio n/exclusion criteria (Section s6.1and 6.2) and as 
described in the paragraphs below .  Subject s taking permitted medicat ions should be on chronic 
stable doses at the baseline visit (Week 0; Visit 2) as specified in Secti on 6.2.  
The fo llowing therapi es will  not be permi tted during the study :  
plaque Pstherapy  as described in the inclusio n/exclusio n criteria (Secti on6.1
and Sect ion 6.2) 
any bio logic therapy  within the washout period specified in Sect ion 6.2
concomitant medicat ions as described in the exclusion criteria
I1F-MC-RHCD (b)Clinical Protocol Page 47
LY2439821live vaccines
phototherapy
The fo llowing m edicat ions will be permitted during the study :
Topical Steroids:  Topical steroi ds (that i s, nonhalogenated steroids/topical calcineurin 
inhibitors administered no more than twice daily ) will be permitted for use limited to the face, 
axilla, and/or genitalia, as needed.  These topical medicat ions should not be used within 
approximately  24hours pr ior to study  visit s.  
Vaccines:  Use of nonlive seasonal vaccinat ions and/or emergency vaccinat ions(such as rabies 
or tetanus vaccinat ions) is allowed.
Other Concomitant Therapies:   
The fo llowing will be allowed as needed:  shampoos that do 
not con tain >3% salicylic acid, corticosteroi ds, coal tar, or vitamin D3 analogues; topical 
moisturi zers/emo llients and other non prescripti ontopical products that do not contain urea, >3% 
salicylic acid, alpha -or beta -hydroxyl acids, corticosteroids, or vitamin D3 an alogues; and bath 
oils and oatmeal bath preparations.
Addit ional drugs are to be avo ided during the study ,unless requi red to treat an AE or for 
treatm ent of an ongoing medical problem.  If the need for concomitant medication arises for an 
AE or for appropri ate medical  management (including the limited use of therapeutic agents 
which, if used under treatment regimens other than for treating an AE or for appropriate medical 
management, might be considered plaque Ps therapi es), the invest igator should base de cisions on 
the subject and clinical factors.  Any addit ional medication, whether prescription or over -the-
counter, used at baseline (Week 0; Visit 2) and/or during the course of the study  must be 
docum ented wi th the start and stop dates on the Conco mitant Medi cations eCRF.
Subject s will maintain their usual medicat ion regimen for other concomitant diseases throughout 
the study , unless specifically excluded in the protocol.  Subject s taking conco mitant medicat ions 
shoul d be on stable doses at baseline (Week 0; Visit 2) and should remain at a stable dose 
throughout the study , unless changes need to be made for an AE or for appropriate medical 
management.  Addit ional systemic drugs are to be avo ided during the study , unless requi red to 
treat an AE.  Other medic ations may be allowed if approved by  the Sponsor or i ts desi gnee.
For subjects who discontinued study treatment and have entered the Post -Treatment Follow -Up 
Period (Peri od 5), plaque Ps therapy  with another agent, as determined appropriate by  the 
investig ator, i s allowed.   Any changes in medicat ions not addressed above should be discussed 
with the invest igator.  Subject s should be instructed to consult the invest igator or other 
appropriate study  personnel at the study  site bef ore taking any new medicat ionsor suppl ements.
7.8. Treatment after the End of the Study
7.8.1. Continued Access
Ixekizumab will not be made available by the Sponsor at the concl usion of the study  to subjects
if the product is commercially available in countries where the subject resides.
I1F-MC-RHCD (b)Clinical Protocol Page 48
LY24398217.8.2. Special Treatment Considerations
Subjects will be screened for eligibilit y in the study as described in Sect ions 6.1and 6.2and will 
be informed of the study -specific restrict ions and requirements of the study .  Subj ects who are 
not willing to comply wit h the study  restri ctions and requirements of the study  will not be 
eligible for enrollment.  
All biological agents carry  the risk of systemic allergic/hypersensit ivity reacti ons.  Clinical  
manifestati ons of  these reactions may include but are not limited to:  
skin rash
pruri tus (i tching)
urticaria (hives)
angioedema (e .g., swelling of the lips and/or tongue)
anaphylactic reaction
Sometimes these react ions can be life -threatening.  Proteins may  also ca use redness, itching, 
swelling, or pain locally at the inject ion site; therefore, all subjects are to be closely monitored 
for signs or symptoms that could result from such reactions, educated on the signs or symptoms 
of these ty pes of  react ions, and instr
ucted to contact the study site immediately if any of the 
symptoms are experienced fo llowing an inject ion.  If a subject experiences an acute 
allergic/hypersensit ivity react ion after an inject ion of study  drug , he or she is to be managed 
appropriately  and given instruction to receive relevant supportive care.  Addit ionally , for an 
event j udged by the invest igator to be a potential systemic allergic/hypersensit ivity react ion, a 
blood sam ple is to be drawn as soon as possible to test for antidrug ant ibodies ( ADAs) 
(Secti on9.4.7 ).
For subjects who experience a potential allergic/hypersensit ivity react ion, consideration for any  
prem edicat ion for future inject ions will be agreed upon between the investigator and the 
Sponsor.  Examples of potential allergic/hypersensit ivity react ions that might merit 
prem edicat ion include mild -to-moderate skin rashes, mild -to-moderate generalized pruritus 
and/or urti caria, and mild to -moderate i nject ion-site reacti ons (e .g., injection -site ery thema, 
inject ion site pruri tus).  Subj ects who develop clinically significant sy stemic 
allergic/hypersensit ivity react ions following administration of study  drug that do not respond to
symptom atic medicat ion or resul t in clinical sequelae or hospitalization are to be discont inued 
from study  treatm ent and not receive further doses of study  drug , with or wi thout prem edicati on 
(see Section 8.1).  Medi cations considered appropriate for premedication include but are not 
restri cted to acetaminophen/paracetamol up to 1000 mg and ant ihistamines (e .
g., oral 
diphenhydramine 50 m g) given aft er all  efficacy  assessments have been completed for a given 
visit and 30 to 60 minutes prior to study drug SC inject ion for visits where inject ions are 
administered at the clinic.  For all other inject ions, subjects may self -premedicate at home prior 
to ad ministration of study  drug , as di rected by  the investi gator.  All  such prem edicat ions will be 
recorded as concomitant medicat ions.  Corti costeroi ds are not permitted as agents for 
prem edicat ion.  
I1F-MC-RHCD (b)Clinical Protocol Page 49
LY24398217.8.3. Permanent Discontinuation from Study Treatment
Discontinuat ion of the study  drug for abnorm al liver tests should be considered by the 
investigator when a subject meets one of the fo llowing condit ions after consultation with the 
Lilly -designated m edical m onitor:
ALT or AST >8xULN
ALT or AST >5xULN for more than 2 w eeks
ALT or AST >3xULN and total bilirubin level (TBL) >2xULN or prothrombin 
time >1.5xULN
ALT or AST >3xULN with the appearance of fat igue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
alkaline phosphat ase (ALP) >3xULN
ALP >2.5x ULN and TBL >2xULN
ALP >2.5xULN wit h the appearance of fat igue, nausea, vo miting, right quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%)
In addit ion, subjects will be discont inued fro m the study  drug under the following 
circumstances:
neutrophil (segmented) counts:
o<500 cells/ L
o≥500 and <1000 cells/ L (based on 2 test results; the second test 
perform ed wi thin 1 week fro m knowl edge of  the ini tial resul t)
o≥1000 and <1500 cells/ L (based on 3 test results) and an infect ion that i s 
not fully  resolved
total WBC count <2000 cells/ L
lymphocy te count <200 cells/μL
platelet count <50,000 cells/μL
Refer to Appendix 5 ,which describes the 95 percent ile BP for age and gender and 
median height .   If subject BP readings is greater than 95 percen tile at 3 consecut ive 
study  visits, study  drug m ust be held unt il the subject’s BP is further assessed.  Following 
that assessment ,a decisio n will be made by Lilly CRP/CRS as to whether the subject 
shoul d remain on the tri al.
the subject experiences a severe AE or an SAE or has a clinical ly significant change in a 
laboratory  value that, in the opi nion of the invest igator, m erits discontinuati on of  the 
study  drug and appropri ate m easures being taken.  This includes evidence of act ive viral 
hepat itis or active TB.  In such cases, Lilly or it s designee is to be notified immediately  
I1F-MC-RHCD (b)Clinical Protocol Page 50
LY2439821clinically significant systemic hypersensit ivity reacti on following SC administration of 
study  drug that does not respond to symptomat ic medicat ion or resul ts in clinical 
sequelae
subject becomes pregnant
subject develops a malignancy
subject has a posit ive TB test using PPD or QuantiFERON®- TB Gol d and i s assessed as 
having latent TB infect ion (see Section9.4.2 ), and/or develops symptom s or si gns of 
tubercul osis
any subject who has a change in disease phenoty pe at any  time (e .g., a change to pustular 
psori asis)
if the subject, for any  reason, requi res treatment with another therapeutic agent that has 
been de monstrated to be effective for the treatment of plaque Ps, di scont inuat ion from 
study  treatm ent occurs pri or to introducti on of  the new agent
enrollment in any other clinical study invo lving an invest igational product or enrollment 
in any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
the invest igator or attending physician decides that the subject should be wit hdrawn fro m 
study  treatm ent
the subject (or caregiver) requests withdrawal from study  treatment
thepatient, at any  time during the study , scores a ≥5for Item  13on the CDRS -
R
-OR
develops active suicidal ideat ion with som e intent to act with or without a specific plan 
(yes to questi on 4 or 5 on the “Suicidal Ideat ion” portion of the Columbia –Suicide 
Severit y Rating Scale [C -SSRS])
-OR
develops suicide -related behaviors as recorded on the C -SSRS.
It is recommended that the subject be assessed by a psy chiatri st or anappropriately 
trained professio nal(e.g.,psychiatrist, clinical psycho logist,social worker etc .) to assist 
in deciding whether the subject is to be discontinued fro m the study .
the invest igator or Lilly stops the subject’s participation in the study  or Lilly  stops the 
study  for m edical, safet y, regul atory , or other reasons consist ent with applicable laws, 
regul ations, and good clinical pract ice (GCP)
All subjects who discont inue from study  treatm ent are encouraged to complete the fo llow-up 
period of  the study .
I1F-MC-RHCD (b)Clinical Protocol Page 51
LY24398218.Discontinuation Criteria
The reason for and date of discont inuat ion from study drug and reason for and date of 
discontinuat ion from study  parti cipat ion will be collected for all rando mized subject s. 
Subject s who discont inue study  drug early will have end -of-therapy  procedures perform ed as 
shown in the Schedule of Act ivities(Secti on 2)and will enter the Post -Treatment Follow -Up 
Period.
Missing data may co mpro mise the integrit y of the study  and undermine the altruist ic contribut ion 
of study  subject s to answer the scient ific quest ions being addressed in the study .  Com plete 
inform ation from each subject is crit ical to achieving the fullest understanding of the potential 
benefits and risks of ixekizumab.  Subjects should make every effort to stay  in the study , to 
attend scheduled visit s, and to take study  drug as medically appropriate .  
Subject swho meet any  of the cri teria described in Section 8.1will be discont inued fro m study  
treatm ent.
8.1. Discontinuation from Study Treatment
The study  will be di scontinued if Lilly or its desi gnee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regul ations, and GCP.
8.1.1. Discontinuation of Inadvertently Enrolled Subjects
The cri teria for enrollment m ust be f ollowed explici tly.  If the Sponsor or invest igator ident ifiesa 
subject who did not meet enrollment criteria and was inadvertent ly enrolled, a di scussio n must 
occur between the Sponsor CRP /CRS and the investigator to determine whether the subject may 
continue in the study .  If both agree i t is m edically  appropriate for the subject to continue, the 
investigator must obtain documented approval from the Sponsor CRP /CRS to allow the 
inadvertent ly enro lled subject to continue in the study with or without treatm ent wi th study  drug .  
8.2. Discontinuation from the Study
Reasons that m ay lead to perm anent di scont inuat ion include:
enrollment in any other clinical study  involving an invest igational product or enrollment 
in any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
medical, safet y, regul atory , or other reasons consistent with applicable laws, regulat ions, 
and GCP
investi gator decisio n
othe invest igator decides that the subject shoul d be discontinued from the study
oif the subject , for any  reason, requi res treatment with another therapeutic agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent
I1F-MC-RHCD (b)Clinical Protocol Page 52
LY2439821subject decision
othe subject or the subject ’sdesignee (e.g.,parent or legal guardian )requests 
withdraw alfrom the study
8.3. Lost to Follow -Up
A subject will be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Study  site personnel are expected to make 
diligent attempts to contact subject s who fail to return for a sc heduled visit or who were 
otherwi se unable to be fo llowed up by the study  site.
I1F-MC-RHCD (b)Clinical Protocol Page 53
LY24398219.Study  Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, wi th the study  procedures and their timing (including 
tolerance limit s for timing).
Appendix 2 lists the laboratory tests that will be performed for this study.
Unless otherwise stated in the subsect ions below, all samples collected for specified laboratory 
tests will be destroy ed wi thin 60 days of recei pt of  confi rmed test resul ts.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
9.1.1. Primary Efficacy Assessments
The co-primary effi cacy endpoint s are PASI 75 and sPGA (0,1) at Week 12.  
The PASI is an accepted primary efficacy  measurement for thi s phase of development of plaque
Ps treatm ents (EMEA [WWW] ).  The PASI combines assessments of the extent of body- surface 
involvement in 4 a natomical regio ns (head and neck, trunk, arms, and legs) and the severit y of 
scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall 
score of 0 for no plaque Ps to 72 for the m ost severe di sease (Fredriksson and Pettersson 1978).  
A clinically  meaningful  response is a PASI 75, which represents at least a 75% decrease 
(improvement) fro m the baseline PASI score.  Higher levels of clearance (PASI 90) as well as 
complete resol ution of plaque Ps (a 100% improvement fr om baseline in PASI score [PASI 100] ) 
areadditional endpoints due to increasing recognit ion of the associat ion of higher clearance with 
greater health -related quali ty of life (Puig 201 5).  
The sPGA is the physician’s glo bal assessment of the subject’s plaque Ps lesions at a given time 
point .  The s PGA is recommended as an endpo int to assess efficacy in the treatment of plaque Ps 
(EMEA [WWW] ).  Plaques are assessed for induration, ery thema, and scaling, and an overall 
rating of plaque Ps severit y is given using the anchors of clear (0), minimal (1), mild (2), 
moderate (3), severe (4), or very  severe (5).  
9.1.2. Secondary Efficacy Assessments
9.1.2.1. Nail Psoriasis Severity Index (NAPSI)
If the subject has fingernail/ toenail  plaque Ps at baseline ,the NAPSI will be used.  The NAPSI is 
a numeric, reproducible, object ive to ol for eval uation of fingerna il/toenail  plaque Ps.  This scale 
is used to eval uate the severit y of fingerna il/toenail bed plaque Ps matrix plaque Ps by area o f 
involvement in the fing ernail/ toenail  unit.  In this study , both fingernail andtoenail  involvement 
will be assessed.  The fingernail/ toenail is divided into imaginary horizontal and longitudinal 
lines into quadrants.  Each nailis given a score for fingernail/ toenail bed plaque Ps (0 to 4) and 
nailmatrix plaque Ps (0 to 4) depending on the presence (score of 1) or absence (score of 0) of 
any of the features of fingernail or toenail bed and matrix plaque Ps in each quadrant.  The 
I1F-MC-RHCD (b)Clinical Protocol Page 54
LY2439821NAPSI score is the sum o f scores in the fingernai l andtoenail  bed and matrix fro m each quadrant 
(maximum o f 8).  Each fingernail andtoenail is eval uated, and the sum  of all the fingernails and 
toenails is the total NAPSI score (range : 0 to 160).
9.1.2.2. Psoriasis Scalp Severity Index
If the subject has scalp plaque Ps at baseline, the Psoriasis Scalp Severit y Index ( PSSI )will be 
used.  The PSSI is a co mposite score derived fro m the sum  of scores for ery thema, induration, 
and desquamation mult iplied by  a score for the extent of scalp area invo lved (range :  0 to 72).
9.1.2.3. Palmoplantar Psoriasis Area and Severity Index
If the subject has palmoplantar plaque Ps at baseline, the Palmoplantar Psoriasis Severit y index 
(PPASI )will be used.  The PPASI is a co mposite score derived fro m the sum  of scores for 
erythema, induration, and desquamat ion mu
ltiplied by  a score for the extent of palm and sole 
area involvement (range :  0 to 72).
9.1.2.4. Percentage of Body Surface Area
The invest igator will  evaluate the percentage involvement of plaque Ps on each subject’s BSA on 
a continuous scale fro m 0% (no invo lvement) to 100% (full invo lvement), in which 1% 
corresponds to the size of the subject’s hand (including the palm, fingers, and thumb) ( Van 
Voorhees et al. 2009).
9.1.2.5. Binary Questions on Psoriasis Location
The binary quest ions for psori asis locat ion will define specific locat ions of plaque Ps.  Thi s 
assessment will be used as a secondary  endpoint and will be especially helpful to delineate the 
presence of psoriasis on the face and in the genital area.  There are no specific scales to assess 
plaque Ps in these l ocati ons.  
9.1.3. Health Outcomes/Quality of Life Measures
9.1.3.1. Itch Numeric Rating Scale
The Itch n umeri c rating scale ( NRS )is a subject -administered, 11 -point horizontal scale 
anchored at 0 and 10, with 0 representing “no itch” and 10 represent ing “worst itch imaginable.”  
Overall severit y of a subject ’s itching fro mplaque Ps is indicated by  circling the number that 
best describes the wo rst level of itching in the past 24 hours.
9.1.3.2. Dermatology Life Quality Index
The Dermatology Life Quality Index (DLQI) will be completed by subject s aged 17 years 
and older.
The DLQI is a simple, subject -administered, 10 -question, validated, qualit y-of-life quest ionnaire 
that covers 6 domains including symptoms and feelings, daily act ivities, leisure, work and 
school , personal  relationships, and treatm ent.  Response categories include “not at all,” “a lot,” 
and “very  much,” wi th corresponding scores of 1, 2, and 3 ,respectively ,and unanswered (“not 
relevant”) responses scored as “0.”  The recall period is “over the last week ,” totals range from  0 
to 30 (l ess to m ore impai rment), and a 5 -point change fro m baseline is considered clinically  
relevant (Basra et al . 2008).  
I1F-MC-RHCD (b)Clinical Protocol Page 55
LY24398219.1.3.3. Children’s Dermatology Life Quality Index
The Children’s Dermatology Life Quality Index (CDLQI) questionnaire will  be completed 
by subject s aged 6 to 16 years of age.
The Children’s Dermatology  Life Qualit y Index (CDLQI) questionnaire is design ed for use in 
children ( subjects from 4 to 16 years of age) (Lewis -Jones and Finlay 1995; Waters et al. 2010; 
Salek et al . 2013) . It consists of 10 items, 6 of which are headings (symptoms and feelings ,
leisure ,school  or holidays , personal relationships, sleep ,and treatm ent). The CDLQI is 
calculated by summing the score of each question ,resul ting in a maximum of 30 and a minimum 
of 0. The higher the score, the more qualit y of life is impaired. The severit y banding for CDLQI 
scores is:
0-1 = no effect on child’s life
2-6 = small effect
7-12 = m oderate effect
13-18 = very  large effect
19-30 = extremely large effect
The CDLQI is self-explanatory  and can be simply  handed to the subject who is asked to 
complete it with the help of a parent or guardian. Itis usually co mpleted in 1to 2minutes.   
The 
recall period is “over the last week, ” total scores range fro m 0 to 30 (less to more impairment), 
and a 5 -point change fro m baseline is considered clinically relevant (Basra et al. 2008).
The Derm atology Life Index (DLQI) will be co mpleted by  subject s aged 17 y ears and ol der. The 
Children’s Dermatology  Life Quali ty Index (CDLQI) questionnaire will  be completed by  
subject s aged 6 to 16 y ears of age. The sites will use the appropriate versio n according to the ag e 
and transit ion from CDLQI to DLQI when the subject turn 17 years old, with the exception 
during the double blind treatment period (induction).
9.1.3.4. Patient’s Global Assessment of Disease Severity
The patient’s global assessment of disease severi ty is a subjec t-administered single -item scale in
which subjects are asked to rank ,by circling a number on a 0- to-5NRS ,the severi ty of their 
plaque Ps “today ” from 0 (clear) = no plaque Ps to 5 (severe) = the worst their plaque Ps has ever 
been.
9.1.4. Appropriateness of Assessments
All o f the clinical and safet y assessments in this study  are standard, widely used, and generally 
recogni zed as reliable, accurate, and relevant.  Immunogenicit y monitoring will provide 
inform ation for future devel opment of ixekizumab.
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subject s who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the subject s.
I1F-MC-RHCD (b)Clinical Protocol Page 56
LY2439821The invest igator is responsible for the appropriate medical care of subject sduring the study .
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate healt hcare opti on, 
AEs that are serious or otherwise medically important, considered related to the study  drug or the 
study , or that caused the subject to discont inue the study  drug before complet ing the study.  The 
subject should be fo llowed unt il the event resolves, stabilizes with appropriate diagnostic 
evaluat ion, or is reasonably  explained.  The frequency of follow -up evaluat ions of the AE is left 
to the di scret ion of the invest igator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the ICF and assent are signed, study  site personnel will record via CRF the occurrence and 
nature of each subjec t’spreexist ing condit ions, including clinically significant signs and 
symptoms of the disease under treatment in the study .  In addition, study site personnel  will 
record any  change in the condit ion(s) and any new condit ions as AEs . Invest igators should 
record their assessment of the potenti al relatedness of each AE to protocol procedure and study  
drug via eCRF.
The invest igator will interpret and document whether an AE has a reasonable possibilit y of being 
related to the study  drug , the study  device, or a study procedure, taking into account the disease, 
concomitant treatment ,or pathol ogies.
A “reasonable possibilit y” means that there is a cause -and-effect rel ationship between the study  
drug, the study  device ,and/or a study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
Planned surg ical procedures and nonsurgical intervent ions should not be reported as AEs ,unless 
the underlying medical condit ion has worsened during the study .
If a subject ’s study  drug is discont inued as a result of an AE, study  site personnel  must report 
this to Lilly or i ts desi gnee via CRF , clarifying, if possible, the circumstances leading to any  
dosagemodificat ions or di scont inuat ion of treatm ent.  
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of death )
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
I1F-MC-RHCD (b)Clinical Protocol Page 57
LY2439821considered significant by  the invest igator for any other reason:  important medical events 
that may  not resul t in death, be life -threatening, or require hospitalization may  be 
considered serious adverse drug events when, based upon appropriate medical judg ment, 
they may jeopardi ze the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definit ion.  Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency ro om or at 
home, blood dyscrasias or convulsio ns that do not result in inpat ient hospi talizat ion, or 
the development of drug dependency or drug abuse
Although all AEs occurring after si gning the ICF are recorded in the CRF and each AE is to be 
assessed as to whether it meets any o f the above serious criteria , the submissio n of SAE reports 
to the Sponsor begins after the subject has signed the ICF and has received study  drug .  
However, if an SAE occurs after signing the ICF but prior to receiving study  drug , it needs to be 
reported to the Sponsor ONLY if it is considered reasonably possibly related to study  procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a Sponsor -approved method.  If alerts are issued via telephone, they  
are to be immediately fo llowed byofficial notificatio n on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow -up SAE 
inform ation.
Pregnanc y (during maternal or paternal exposure to study  drug ) does not m eet the definit ion of 
an AE.  However, to fulfill regulatory  requi rements any pregnancy  should be reported according
to the SAE reporting process to provide data to the Sponsor on the outcome for both m other and 
fetus.
Invest igators are not obligated to actively seek AEs or SAEs in subject s once they  have 
discontinued and/or completed the study  (the subject summary CRF has been completed).  
However, if the invest igator learns of any SAE, including a death, at any  time after a subject has 
been discharged from the study  and he or she considers the event reasonably possibly related to 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
9.2.1.1. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that are assessed as being related to study drug or procedure.  United States 21 CFR 
312.32 and EU Clinical Trial Direct ive 2001/ 20/EC and the associated detailed guidance or 
national regulatory  requi rements in parti cipat ing countries require the reporting o f SUSARs.  
Lilly has procedures that will be fo llowed for recording and expedited reporting of SUSARs that 
are consistent with global regulati ons and the associ ated detailed guidances.
9.2.2. Adverse Events of Special Interest
The fo llowing adverse events of special interest (AESIs) will be evaluated in specifically to 
determine the safet y and tol erabili ty of ixekizumab over the range of doses selected for this 
clinical study .
I1F-MC-RHCD (b)Clinical Protocol Page 58
LY2439821AESIs for ixekizumab are:
cytopeni as (leukopenia, neutropenia, and thrombocy topeni a)
liver biochemical test changes/enzyme elevat ions (ALT, AS T, bilirubin, and ALP)
infect ion
immunogenicit y
inject ion-site reacti ons
allergic reactions/hypersensit ivities
cerebrocardiovascular events
malignancies
depressio n
inflammatory  bowel  disease
interstitial lung disease
If infections, inject ion-site reacti ons, or allergic/hypersensit ivity react ions are reported, study 
sites will provi de details on these events as instructed on the eCRF.  Invest igators will also 
educate subjects and/or caregivers about the symptoms of allergic/hypersensit ivity react ions and 
will provide instructions on dealing with these reactions (see also Section 7.8).  A blood sample 
will be co llected when possible for any subject who e xperiences an AE of allergic
reacti ons/hypersensi tivitiesduring the study .
Data on suspected inflammatory  bowel  disease, as ident ified by events possibly indicat ive of 
ulcerat ive co litis and Crohn’s disease, will be co llected ,and the events will be adjud icated by  an 
external Clinical Events Committee (CEC) composed of gastroenterologists with expert ise in 
inflammatory  bowel  disease .  The rol e of the CEC is to adjudicate defin ed clinical events in a 
blinded, consistent, and unbiased manner throughout a stu dy.The importance of the CEC is to 
ensure that all events that have been reported are evaluated uniformly by a single group.
9.2.3. Complaint Handling
Lilly co llects product complaints on study  drug s and drug delivery  systems used in clinical 
studi es to ensure the safet y of study  parti cipants, moni tor qualit y, and f acilitate process and 
product improvements.
Subject swill be instructed to contact the invest igator as soon as possible if they have a com plaint 
or probl em with the study  drug so that the situation ca n be assessed.
9.3. Treatment of Overdose
Refer to the ixekizumab IBand/or Product Label for the adul t indicat ion (ixekizumab and/or 
comparator).
9.4. Safety
9.4.1. Physical Examination
One co mplete physical examinat ion (excluding pelvic, rectal, and breast examinat ions) will be 
perform ed at screening (Visit 1).  This examinat ion will determine whether the subject meets the 
I1F-MC-RHCD (b)Clinical Protocol Page 59
LY2439821criteria requi red to parti cipate in the study  and will al so serve as a m onitor for preexi sting 
condi tions and as a baseline for treatment -emergent adverse event (TEAE) assessment.  All 
physical examinat ions throughout the study  shoul d incl ude a symptom -directed physical  
evaluat ion as well as an examinat ion of the heart, lungs andabdo men and a visual examinat ion 
of the skin.  
9.4.2. Chest X -Ray and Tuberculosis Testing
A posteri or-anterior view chest x -ray will be obtained, unless the x -ray or resul ts from a chest 
x-ray obtained wi thin 6 m onths pri or to the study  are available .  The chest x -ray or resul ts will  be 
reviewed by  the invest igator or designee and considered al ong wi th the subject ’s medical history , 
assessment of risk factor for M. tuberculosis infectio n and physical examinat ionto excl ude 
subjects with active TB infe ction.  In Germany, a chest x -ray has to be performed wit hin 
6months pri or to si gning inform ed consent indicating no evidence of TB .
In addit ion, subjects will be tested at screening as indicated inthe Schedule of Act ivities 
(Secti on2) for evi dence of M. tuberculosis infect ion.  Apositive tuberculin PPD skin test 
response for this study  is defined as ≥5-mm induration between 48 and 72 hours after PPD
applicat ion, regardl ess of BCG vaccinat ion history.  In countries where an interferon-
gamma 
release assay (Quant iFERON ®-TB Gold test ) is available and, in the judgment of the 
investigator ,ispreferred as an alternat ive to the PPD skin test for the evaluat ion of M. 
tuberculosis infect ion, it m ay be used instead of the PPD test and may  be read l ocally.  If the 
Quant iFERON ®-TB Gol d test i s indeterminate, 1 retest is allowed.  If the retest for t he 
Quant iFERON ®-TB Gol d test i s indeterminate, the subject is excluded fro m enrollment in the 
study .
Subjects with documentati on of  a negat ive PPD or Quant iFERON® -TB Gol d test (TB test) 
resul t within 3 months pri or to baseline (Week 0; Vi sit2) are not req uired to have a TB test at 
Visit 1unless medical history , including assessment for TB infect ion risk factors, chest x -ray or 
physical examinat ion indicates that testing should be done . Documentati on of  this test resul t 
must include a record of the size o f the induration response (<5- mm indurat ion)or the laboratory  
report of the Quant iFERON ®-TB Gold test result .  A PPD test recorded as negative without 
docum enting the size of indurat ion will requi rea retest.
Subjects with a PPD skin test ≥5 mm indurati on or a posi tive Quant iFERON ®-TB Gold but no
evidence of active TB ,and subjects who have a docum ented history  of a posi tive TB test but no 
docum ented history  of completion of a full, appropri ate latent TB treatm ent course ,who are 
assessed as having latent TB infect ion may be re -screened 1 time and may be enrolled wit hout 
repeating a PPD or QuantiFERON ®-TB Gol d test if the following condit ions are m et:
after receiving at least 4 weeks of appropriate latent TB infection therapy  with
no evidence of hepatotoxi city (ALT/AST m ust remain ≤2x ULN) upon 
retesting of serum ALT/AST prior to randomizat ion,
commit ment by  the subject and the caregiver for the subject to complete a full 
course of standard prophylaxis for TB ,and
I1F-MC-RHCD (b)Clinical Protocol Page 60
LY2439821meet all other inclusio n/exclusio n criteria for partici pation.
Such subjects must complete appropriate latent TB infect ion therapy  to rem ain eligible
for continued study  parti cipat ion.If rescreening occurs within 6 months of the screening 
chest x -ray, a repeat of chest x -ray for considering enro llment is not required.
If a subject with a positive PPD or QuantiFERON®- TB Gold is fully assessed by the 
investigator and the invest igator determines that th e subject has no risk factors for and no 
symptoms or signs of M. tuberculosis infection, the Invest igator maycontact the Lilly 
Medical Monitor to discuss the possibilit y of a false-positive test result.
Subjects with positive TB test results on file :  Subjects with a docum ented prior history  of a 
positive TB test and subjects who have a docum ented history  of com pletion of an appropriate TB 
treatm ent regimen for latent or active TB shoul d not have a TB test performed at Visit 1.  Such 
subjects wi thno history  of re-exposure to TB since their treatment was completed and no 
evidence of act ive TB are eligible to participate in the study .  Subjects who have had househo ld 
contact wi th a person wi th active TB are excluded unless an appropriate and documented course 
of prophylaxis for TB was completed.
Subjects are to be monitored on a regular b asis for any symptom sor signsof active TB and for 
any new risk factors for TB infection , with full medi cal evaluat ion including TB testing when 
medically indicated . Subject s that exhibit symptoms of act ive TB shoul d be referred to a 
specialist in the care of subject s with TB. 
Any clinically  significant findings from chest x -rays and/or TBtesting that result in a diagnosis 
and that occur after the subject signs the ICF should be reported to Lilly  or its design ee as an AE
viaeCRF.
9.4.3. Electrocardiograms
For each subject , 1electrocardiogram (ECG) should be collected according to the Schedule of 
Activities (Secti on 2).  The ECG should be recorded according to the study -specific 
recommendat ions included in the ECG Manual for the study .  Subject s must be supine for a 
minimum o f5 minutes before ECG collect ion and rem ain supine during ECG collect ion.  
A single ECG will be obtained at Visit 1 and read by  a qualified physician (the invest igator or 
qualified designee) at the study  site to determine whether the subject meets entry  criteria.  The 
screening (Visit 1) ECG will subsequently be electronically  transmitted to the centralized ECG 
vendor designated by  the Sponsor.  The centralized ECG vendor’s cardio logist will co mplete an 
ECG overread before rando mizat ion to confirm that the subject meets entry  criteria. 
ECGs may be obtained at addit ional times, when deemed clinically  necessary .  Collecti on of  
more ECGs than expected at a particular time point is allowed when needed to ensure high 
qualit y records.
ECGs after Vi sit 1 will  be interpreted by  a qualified physician at the study  site as soon after ECG 
collect ion as possible, ideally  while the subject is still present ,for immediate subject
management should any clinically relevant findings be identified.
I1F-MC-RHCD (b)Clinical Protocol Page 61
LY2439821If a clinically significant quantitative or qualitat ive change fro m screening (Visit 1) is identified
after randomizat ion, the invest igator will assess the subject for symptom s (e.g., palpitations, near 
syncope, syncope) and determine whether the subject can continue in the study .  The invest igator 
or qualified designee is responsible for determining whether any change in subject management 
is needed and must document his or her review of the ECG printed at the time of evaluat ion.
Any clinically  significant findings from ECGs that result in a diagnosis of untoward cardiac 
event and that occur after th e subject receives the first dose of the study  drug shoul d be reported 
to Lilly  or its desi gnee as an AE via CRF.
The invest igator (or qualified designee) must document his or her review of the ECG printed at 
the time o f evaluation, the final overread ECG report i ssued by  the central  ECG laboratory , and 
any alert reports.
9.4.4. Bone Imaging
A Bone Age Imaging X-raywill be performed on the left hand twice   at Visit 2 (Week 0) and 
Visit31 (Week 108) according to schedule of act ivities.  ICH gui delines requi re tha t we m onitor 
the growth and development of pediatric subject s systematically  for all  drugs studi ed in this age 
group (ICH guidelines).  The bone age indicates the level o f biological  and structural  maturity 
and can deviate fro m chrono logical age calculated from  the date of birth. Pubertal progress will 
bemonitored by  clinical tanner staging in associat ion with lo ngitudinal growth.
9.4.5. Vital Signs
Vital sign m easurements shoul d be conducted according to the Schedule of Act ivities 
(Secti on2).
Any clinically  significant findings from vita l sign measurement that result in a diagnosis and that 
occur after the subject receives the first dose of study  drug shoul d be reported to Lilly  or its 
designee as an AE via CRF.   
To be collected as per standard clinical practice. 
9.4.6. Laboratory Tests
For each subject , laboratory  tests detailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Act ivities (Secti on 2).  
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the subject receives the first dose of study  drug shoul d be reported to Lilly  or its designee as 
an AEvia CRF .
9.4.7. Immunogenicity
Samples for immunogenicit y testing will be collected at time points indicated in the Schedule of 
Activities (Section 2)and for an event judged by  the invest igator to be a potential systemic 
allergic/hypersensit ivity react ion, when possible.  Venous blood samples (approximately 2mL) 
will be co llected into tu bes and used to determine ant ibody  producti on against ixekizumab.  The 
actual date of each sampling will be recorded on the laboratory  requisi tion.
I1F-MC-RHCD (b)Clinical Protocol Page 62
LY2439821Immunogenicit y will be assessed by  a validated assay  designed to perform  in the presence of 
ixekizumab.  Antibodies may be further characterized and/or evaluated for their abilit y to 
neutralize the activit y of ixekizumab.  Treatment -emergent immunogenicit y is defined as any 
occurrence of a 4- fold or 2 -dilution increase in titer over the pretreatment baseline tit er.  In the 
case of a negative result at baseline, treatment -emergent immunogenicit y is defined as an 
increase in titer to ≥1:10.  
Samples may  be stored for a m aximum of 15 y ears f ollowing l ast subject visit to enable further 
analysis of immune responses to ixekizumab. The durati on allows the Sponsor to respond to 
regul atory  requests rel ated to the study  drug .
Blood sam ples f or PK assessment will be time- matched to immunogenicit y samples for analysis 
of ixekizumab serum concentrations to facilitate in the interpretation o f the immunogenicit y data 
(see Section 9.5).
9.4.8. Safety -Related Immune Markers
Interl eukin-17 is believed to play a role in neutrophil homeostasis and in neutrophil -dependent 
host defense against extracellular infect ions (Happel et al. 2003; Huang et al. 2004; Milner et al. 
2008).  Neutrophil counts will therefore serve as a safet y marker in the current invest igation.
Ixekizumab is not e xpected to affect the numbers of B, T, and NK lymphocy tes or serum  
immunogl obulin subclasses A, G, and M (IgA, immunoglobulin G , and immunoglobulin M, 
respectively ) in peripheral  blood.  However, since thi s is a novel immuno modulatory  drug, these 
param eters will be measured in subject saccording to the Schedule of Act ivities (Section 2).
9.4.9. Children’s Depression Rating Scale
The Children's Depressio nRating Scale –Revised (CDRS-R) (Poznanski and Mokros 1996) is the 
most wi dely used rating scale for assessing severit y of depressi on and change in depressive 
symptoms for clinical research studi es in children and ado lescents with depressio n. The 
CDRS -R was originally  devel oped as a rating scale for children aged 6 to 12 years.  It is a 
17-item scale, with items ranging from 1 to 5 or 1 to 7 ( the total score is the sum of the 17 items 
and ranges fro m 17-113, with higher scores indicating more depressive sympt oms) and is rated 
by a clinician via interviews with the child and parent or legal guardi an. A score of ≥40 is 
indicat ive of depressio n, whereas a score ≤28 is often used to define remissio n (minimal or no 
symptoms) (May es et al . 2010) . Subjects will be assessed according to the Schedule o f 
Activities (Section 2).
9.4.10. Columbia –Suicide Severity Rating Scale
Children age d
11years and y ounger will  use the Children CSSRS form and those 12 years and 
older will use the Adult CSSRS. The sites will use the appropriate version according to the age 
and transit ion from one versio n to the other when the subject turns 12years o ld, with the
exception during the double -blind treatment period ( Period2, Induction).
The C -SSRS (Posner et al. 2007; C- SSRS website [WWW]) i s a scale that captures the 
occurrence, severit y, and f requency  of suicide -related i deations and behaviors during the 
I1F-MC-RHCD (b)Clinical Protocol Page 63
LY2439821assessme nt period.  The C -SSRS m ust be administered by  appropriately  trained study  site 
personnel.  The tool was developed by  the Nat ional Inst itute of Mental Healt h Treatm ent of  
Adolescent Sui cide Attem pters Study Group as a counterpart to the Columbia Classifica tion 
Algori thm of Suicide Assessment categorizat ion of sui cidal  events.  Subject s will be assessed 
according to the Schedule of Act ivities (Secti on 2).
The Self -Harm  Supplement Form is a 1 -question eCRF questionnaire that is completed at any 
visit, including baseline visits, asking for the number of suicidal or nonsuicidal self -injuri ous 
behaviors the subject experienced since last assessment.  For e ach unique event ident ified, a 
questionnaire (Self -Harm  Follow
-Up Form ),which co llects supplemental informat ion on the 
self-injuri ous behavior ,must be completed.  This informat ion is then documented in the eCRF.  
9.4.11. Tanner Stage Scale
The Tanner Stage Scales are a series of line drawings that are designed to aid the invest igator in 
appropriately  assessing the sexual maturi ty of the subject .  Data gathered will be assessed to 
determine that no pubertal disruption has occurred during the study . Although t he line drawing s
were originally intended for child self- assessment; evidence suggests that pubertal assessment by  
the child or the parents /legal guardian is not a reliable measure of exact pubertal staging and 
shoul d be augmented by  a physical examinat ion(Rasmussen et al. 2015) .  The drawings will be 
used by the derm atologistinvest igator as an aid .  Subjects will be assessed according to the 
Schedule of Act ivities (Section 2).  
9.4.12. Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by appropri ate 
methods.
If a study  subject experiences elevated ALT ≥3xULN, ALP ≥2xULN, or el evated TBL ≥2xULN, 
clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator.  Details for hepatic 
monitoring depend on the severit y and persistence of observed laboratory  test abnorm alities.  To 
ensure subject safety and co mply with regul atory  guidance , the investi gator i s to consult wi th the 
Lilly Medical  Moni torregarding collect ion of specific reco mmended clinical information and 
follow
-up laboratory  tests.  See Appendix 4 .
In the event that safet y monitoring uncovers an issue that needs to be addressed by unblinding at 
the group l evel, only  members of the DMC (an advisory  group for this study  formed to protect 
the integrit y of data; refer to Section 10.4.8 , Interim Analyses) can conduct addit ional analyses 
of the safet y data.
9.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Act ivities(Secti on 2),venous blood samples 
of approximately  
2mL each will be collected to determine the serum  concentrati ons of 
ixekizumab .Two addit ional PK samples will be taken during Period 2, Induction in subjec ts 
who participate in the PK/PD addendum  (see P rotocol  Addendum  I1F-MC-RHCD [1]for 
details).
I1F-MC-RHCD (b)Clinical Protocol Page 64
LY2439821A maximum of 3 samples m ay be drawn at addit ional time po ints during the study  if warranted 
and agreed upon between both the invest igator and Sponsor.  Instructions for the collect ion and 
handling of blood samples will be provided by  the Sponsor .  The actual date and 24- hour clock 
time of each sampling will be recorded.
Drug concentration informat ion that m ay unblind the study  will not be reported to invest igative 
sites or blinded personnel unt il the study has been unblinded.
Bioanaly tical samples collected to m easure study drug concentration will be retained for a 
maximum o f 1 year following l ast subject visit for the study .
9.6. Pharmacodynamics
Not applicable.
9.7. Pharmacogenomics
Not applicable.
9.8. Biomarkers
Not applicable.
9.9. Medical Resource Utilization and Health Economics
Not applicable.
I1F-MC-RHCD (b)Clinical Protocol Page 65
LY243982110.Statistical Considerations
10.1. Bone Imaging 
A Bone Age Imaging X-raywill be done on the left hand twice.  ICH guidelines require that we 
monitor the growth and development of pediatric subject s system atically for all drugs studied in 
this age group (ICH gui delines).  The bone age indicates the level of bio logical  and structural  
maturit y and can deviate from chronological age calculated from the date of birth. Pubertal 
progress i s generally  monitored by  clinical  tanner staging in associat ion with longitudinal 
growth.
10.2. Sample Size Determination
Sample size of this study  is based on the regulatory requirements from the European Medicine’s 
Agency Paediatri c Investi gation Plan for ixekizumab .  The regul atory  requi rements for the
number of subjects in each treatment group were:(1) at least 170 randomi zed subjects (at least 
90to ixekizumab, at least 25 to etanercept ,and at least 55 to placebo) and (2) at least 30% of 
subjects from the EU.
For thi s study , approximately  195 subjects will be rando mized. Approximately 165 subjects will 
be randomized in a 2:1 rati o to receive ixekizumab (110 subjects) or placebo (55 subjects) during 
the Doubl e-Blind Treatment Period.  Approximately 30 subjects will be rando mized to 
etanercept ;details are described in the P rotocol  Addendum I1F-MC-RHCD(2) .
The study  will have >99% power to test the superiority  of ixekizumab to placebo for PASI 75 
and for sPGA (0,1) at Week 12 based on the 2-sided Fisher exact test at a significance l evel of 
0.05.  The fo llowing assumpt ions were used for the power calculations for both sPGA (0,1) and 
PASI 75 responses rates based on ixekizumab clinical studi es in adult subject s with moderate -to-
severe plaque Psefficacy  data (Griffit hsetal. 2015; Gordon et al. 2016
): 80% response for
ixekizumab and 10% response for placebo for both PASI 75 and sPGA (0,1) .  
10.3. Populations for Analyses
For purposes of analysis, the following populat ions are defined:
Population Description
ITT All randomized subject s, even if the subject does not take the assigned treatment, does not 
receive the correct treatment, or otherwise does not follow the protocol. Unless otherwise 
specified, efficacy and health outcomes analyses will be conducted on th e ITT Population 
during the Double -Blind Treatment Inductio n Period (Period 2).  Subject s will be analyzed 
according to the treatment to which they were assigned.
Per-Protocol All randomized subject s who do not have significant protocol violations. Subje cts will be 
analy zed according to the treatment to which they were assigned.  The co-primary  analy ses 
(PASI 75 and sPGA [0,1])will be repeated using the per -protocol set during the Double -Blind 
Treatment Period.
Safety All randomized participants who take at least 1 dose of double -blind study  treatment. Subjects 
will be analyzed according to the treatment to which they were assigned.
Safety analyses for the Post-Treatment Follow -Up Period will be conducted on the Follow -Up 
Population, defined as all r andomized subject s who received at least 1 dose of study treatment 
I1F-MC-RHCD (b)Clinical Protocol Page 66
LY2439821and have entered the Post -Treatment Follow -Up Period.
All Ixekizumab All randomized subjects who receive at least 1dose of ixekizumab .  Efficacy and safety 
analy ses will be conducted on t his population .  
Abbreviations:  ITT = intent to treat ; PASI 75 = at least a 75% improvement from baseline in Psoriasis Area and 
Severity  Index score ; sPGA = static Physician’s Global Assessment .
10.4. Statistical Analyses
10.4.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly o r its desi gnee.
Efficacy and safety analyses will be conducted for the Doubl e-Blind Treatment Induction Period 
(Period2) and all ixekizumab treatment period s(defined as the total tim e subject is receiving
ixekizumab during the study ).
Unless otherwise specified, e fficacy and heal th outcom esanalyses during Period 2, Induction 
will be conducted on the ITT Population. Efficacy and health outcomes will be summarized 
during the overall ixekizumab treatment period for allsubjects who are randomized to 
ixekizumab group at Week 0 and co mbining all the ixekizumab treatment periods.
Safety analyses during the Period 2 , Induct ionwill be conducted on the Safety Population. 
Safety analyses during the overall ixekizumab treatment period will be conducted for all subjects 
who receive at least 1dose of ixekizumab and combining all the ixekizumab treatment periods.
Continuous data will be summari zed in term s of the m ean, standard deviat ion, minimum, 
maximum, median, and number of observat ions.  Categorical data will be summari zed as 
frequency counts and percentages.  Comparisons between ixekizumab and placebo will be 
perform ed for all analyses in the Double -Blind Treatm entInduction Period(Peri od 2) . 
Unless otherwise specified, b aseline for efficacy  and heal th outcom es during Peri od 2, Induction
and during the overall ixekizumab treatment period is at or prior to the first inject ion of study  
drug.  In most cases, this will be the measure recorded at Week 0(Visit 2) .If the subject does not 
receive any injecti on, the l ast available value on or prior to randomization date will be used.  
Change from baseline will be calculated as the visit value of interest minus the baseline value.
Unless otherwise specified, b aseline for safet y during Peri od 2, Induction is defined as follows:  
for categori cal data, baseline includes all available values before the first inject ion at Week 0 ; for 
continuous data, baseline is the last available value before the first inject ion at Week 0 .  Baseline 
for categori cal safet ydata during the overall ixekizumab treatment period is defined as all 
available values if ixekizumab is received at Week 0 and the las t available value prior to fi rst 
dose of ixekizumab when ixekizumab is administered after Period 2 , Induction .  
For the Post -Treatment Follow -Up Peri od (Peri od 5), baseline is defined as the last nonmissing 
assessment on or prior to entering Period 5 , that is, on or pri or to Week 108 or ETV.
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to the data analysis 
I1F-MC-RHCD (b)Clinical Protocol Page 67
LY2439821methods described in the protoc ol and the j ustificatio n for making the change will be described 
in the clinical study  report (CSR). Additional exploratory analyses of the data will be conducted 
asdeemed appropriate. 
Com plete details of the planned analyses will be documented in the statistical analysis plan.
10.4.2. Analysis Methods
The primary  analyses method for categorical data comparison between treatments will be the 
Fisher ’sexact test. Differen ceof the proporti onsand the 95% CIof the difference will be 
included.
Secondary  analyses for the co-primary efficacy measure sPASI 75 and sPGA (0,1) will be 
conducted using a logistic regressio n analysis wit h treatm ent group, region , baseline sPGA score 
(severit y of the psori asis),and baseline weight category  (<25 kg, ≥25 to ≤50kg, >50kg) as 
factors. The odds ratio and the corresponding 95% CIwill be reported. 
The analyses for the continuous efficacy and healt h outcom esvariables will be made using 
analysis of covariance (ANCOVA ) and using a mixed model for repeated measures (MMRM)
analysis ).  The ANCOVA model includes treatm ent, region , baseline sPGA score , baseline 
weight category ,and baseline value. Type III sums of squares for the least-squares means will 
be used for the statist ical compar ison; the 95% CI will be reported.
When the MMRM is used, the model will include treatment, region, baseline sPGA score , 
baseline weight category , baseline value, visit, treatment -by-visit,and baseline -by-visit 
interact ions as fixed factors. The covariance structure to model the within -subject errors will be 
unstructured. The Kenward -Roger m ethod will be used to estimate the denominator degrees of 
freedo m. Type III tests for the least -squares means will be used for the statist ical co mpar ison; 
the 95% CI will be reported. Treatment comparisons at Week 12 and all other postbaseline visit s
in Period 2, Inducti onwill be reported. If the unstructured covariance matrix results in a lack of 
convergence, the heterogeneous Toeplitz covariance structure, followed by  the heterogeneous 
autoregress ive covariance structure, fo llowed by the com pound symmetry  will be used. This 
order i s specified according to a decreasing number of covariance parameters in the structure. 
The san dwich est imator (Diggle et al. 1994) for the covariance est imation will b e used by  
specifying the EMPIRICAL option in SAS PROC MIXED. When sandwich est imation is used, 
the Kenward -Roger approximat ion for denominator degrees of freedo m cannot be used. Instead, 
DDFM= BETWITHIN option will be used to estimate deno minator degrees of freedo m.
Treatment comparisons of time to relapse (sPGA ≥ 2) will be conducted using the log- rank test
as described in Protocol Addendum I1F-MC-RHCD (2).
10.4.2.1. Missing Data Imputation
The m ethods for imputati on of  missing data to be used in this study  are in accordance wi th the 
precedent set in other Phase 3 plaque Ps studi es (Griffithset al. 2015; Gordon et al. 2016).
I1F-MC-RHCD (b)Clinical Protocol Page 68
LY243982110.4.2.2. Nonresponder Imputation
Analysis of categorical efficacy and healt h outcome svariables will be assessed using a 
nonresponder imputation ( NRI)method. Subject s will be considered non responder sfor the NRI 
analysis if they  do not m eet the clinical response criteria or have missing clinical response data at 
the analysis t ime point. Randomized subject s without at least 1 postbaseline observation w ill 
also be defined as nonresponders for the NRI analysis.
10.4.2.3. Last Observation Carried Forward
A last observat ion carri ed forward analysis will be performed on all cont inuous efficacy and 
healt h outcom es variables as a secondary  analysis. For subject s having missing data at the visit, 
the last non missing postbaseline observation before the missing data will be carried forward to 
the corresponding time point for evaluat ion. Subjects who have a baseline and at least 
1postbaseline observation will be included for evaluat ion.
10.4.3. Adjustment for Multiple Comparisons
A multiple testing str ategy  for the co-primary and major secondary  objectives will be 
implemented to control the family -wise Type I error rate at a 2 -sided αlevel of 0.05. The 
primary  and key secondary  com parisons will be tested by  using the primary analysis method, 
Fisher exact test ,with NRI missing data imputation approach.
A gatekeeping approach will be used for multiple com parisons to control the family -wise error
rate. The following endpoints willbe tested:
Primary 1:  Proporti on of subject s achieving PASI 75 at Week 12
Primary 2:  Proporti on of  subject s achieving sPGA (0,1) at Week 12
Secondary 1:  Proporti on of  subject s achieving PASI 90 at Week 12
Secondary 2:  Proporti on of  subject s achieving sPGA (0) at Week 12
Secondary 3:  Proporti on of  subject s achieving PASI 100 at Week 12
Secondary 4:  Proportion of subjects achieving ≥4 point improvement at Week 12 for subjects 
who had a baseline Itch NRS ≥4 
Secondary 5:  Proporti on of  subjects achieving PASI 75 at Week 2
Secondary 6:  Proporti on of  subjects achieving sPGA (0,1) at Week 2
The Primary 1will first be tested at 2 -sided α=0.05. If successful , the test for Primary 2 will be
perform ed at 2 -sided α=0.05. Otherwise, the test will stop. If the Primary 2 endpo int is 
successful, the Secondary  1endpo int will be tested. The test will cont inue to the last endpoint if 
all the prior tests are successful. If atest i s not successful, all subsequent tests will no t be 
perform ed.
10.4.3.1. Subject Disposition
All subject s who discont inue from study  treatm ent and from the study  will be ident ified, and the 
extent of their participat ion in the study will be reported. If known, a reason for discont inuat ion 
will be given. Subjectdisposit ion will  be summarized for each treatment period with reasons for 
I1F-MC-RHCD (b)Clinical Protocol Page 69
LY2439821discontinuat ion. The reasons for discontinuation during Period 2, Induction will be compared 
between treatm ent group susing Fisher ’sexact test.
10.4.3.2. Subject Characteristics
The subject ’sage, gender , ethnicit y, weight, hei ght, BMI , habits, and other dem ographic 
characterist ics will be recorded. Baseline disease severit y (including sPGA score and PASI 
score), age of plaque Ps onset, disease location (nails, scalp, hands, and feet ), and previous 
plaque Ps therapy  type will also be recorded and reported.
Subject baseline characterist ics will be summarized by  treatm ent group and overall for the ITT 
popul ation.  C omparisons between treatm ent groups for the ITT population will be conducted 
using Fisher ’sexact test for categorical data and an analysis o f variance model with treatm ent 
group as a factor for continuous data.
10.4.3.3. Concomitant Therapy 
Previous and concomitant medicat ions will be summarized for subject s for Period 2, Inducti on
will be presented by World Healt h Organization Anatomic Therapeut ic Class Level 4 and 
preferred term. Previous plaque Ps therapy  will be summarized according to the ty pe (topi cal, 
biologics, nonbio logics, phototherapy , and so on). The comparisons betw een treatm ent group sin 
Period 2, Induction will be conducted using Fisher ’sexact test.
10.4.3.4. Treatment Compliance
Treatment compliance wit h study  drug will be summarized for subject s who were randomized in 
Period 2.A subject will be considered co mpliantfor each study  periodif heor she misses no 
more than 20% of the expected doses, does not miss 2 consecut ive doses, and does not over dose
(that i s, receive more injections at the same time point than specified in the protocol). 
Proporti ons of subject s com pliant overall  will be com pared between treatm ent groups during 
Period 2, Induction using Fisher ’sexact test.
10.4.4. Efficacy Analyses
10.4.4.1. Co-Primary Analyses
The co-primary analys es will be based on the ITT Population for Peri od 2, Inducti on.  In 
addition, an analysis o f the Per-Protocol Population will be used to support the primary  efficacy  
analys es.
Treatment comparisons in the proportion of subject s achieving PASI 75 response and sPGA (0,1) 
response at We ek 12 will be analyzed using Fisher’sexact test.  Missing data will be imputed 
using the NRI method described in Sect ion10.4.2.2 .  Table RHCD. 3includes the co -primary 
analysis variables and the methods.  
10.4.4.2. Major Secondary Analyses
Unless otherwise specified, t he major secondary analyse s at Week 12 will be based on the ITT 
Populationfor Period 2, Inducti on.  The major secondary comparisons will be tested based on 
the gate keeping approach described in Section 10.4.3 .  Treatment compar isons in the proportion 
of subject s achieving a response at Week 12 will be analyzed using Fisher ’sexact test.  Missing 
I1F-MC-RHCD (b)Clinical Protocol Page 70
LY2439821data will be imputed using the NRI method described in Section 10.4.2.2 .  Table RHCD. 3
includes the secondary  analysis vari ables and the methods.  
10.4.4.3. Other Secondary Analyses
Unless otherwise specified, the other secondary  analyses for Peri od 2, Induction will be based on 
the ITT Population and safet y populati on.  There will be no adjust ment for multiple com parisons 
for other secondary  analyses.  
The other secondary  analyses incl ude the secondary  analyses and comparisons for the co-primary 
efficacy  outcom esPASI 75 and sPGA (0,1) and the analyses for secondary efficacy outcomes.  
Table RHCD. 3includes the secon dary analysis variables and methods.  The detailed methods are 
specified in Section 10.4.2.2 .  The treatm ent comparisons include ixekizumab versus placebo at 
Week 12 and all other postbaseline visits during Peri od 2, Induction (the time course of response 
to treatment).
I1F-MC-RHCD (b)Clinical Protocol Page 71
LY2439821Table RHCD. 3. Efficacy A nalyses
Efficacy Measure Variable Analysis
PASI PASI 75 ( co-primary efficacy 
outcome)Fisher ’sexact test with NRI (primary analysis) ;
Logistic regression
PASI 90 (major secondary efficacy 
outcome)Fisher ’sexact test with NRI
PASI 100 (major secondary efficacy 
outcome)Fisher ’sexact test with NRI
Change f rom baseline percent 
improvementANCOVA with LOCF
MMRM
sPGA sPGA (0,1) ( co-primary efficacy 
outcome)Fisher ’sexact test with NRI (primary analysis) ;
Logistic regression
sPGA (0) (major secondary efficacy 
outcome)Fisher ’sexact test with NRI
BSA Change f rom baseline ANCOVA with LOCF
MMRM
NAPSI (subjects with 
baseline nail involvement)Change f rom baseline ANCOVA with LOCF
MMRM
PSSI ( subject s with 
baseline scalp 
involvement)Change f rom baseline ANCOVA with LOCF
MMRM
PPASI ( subject s with 
baseline palmoplantar 
involvement)Change f rom baseline ANCOVA with LOCF
MMRM
Binary  questions on 
psoriasis location (by 
subjects who have 
psoriasis presence within 
the specified psoriasis 
location)Achieving resolution of psoriasis 
within the specified psoriasis 
locationFisher ’sexact test with NRI
Abbreviations:  ANCOVA = analysis of covariance; BSA = body surface area; LOCF = last observation carried 
forward; MMRM = mixed model for repeated measures; NAPSI = Nail Psoriasis Severity Index; 
NRI =nonresponder imputation; PASI = Psoriasis Area and Sev erity Index; PASI 75 = at least a 75% 
improvement from baseline in PASI score; PASI 90 = at least a 90% improvement from baseline in PASI score; 
PASI 100 = a 100% improvement from baseline in PASI score; PPASI = Palmoplantar Psoriasis Area and 
Severity  Index; PSSI = Psoriasis Scalp Severity Index; sPGA = static Physician ’sGlobal Assessment.
10.4.5. Safety Analyses
Safety of ixekizumab, including but not limited to infect ions;injection -site reacti ons; B- , T-, and 
NK-cell levels ;WBC count; RBC count; and laboratory  values (hematology  and chemistry  
[including ALT and AST] )will be assessed .  
Exposure to study drug ;AEs; laboratory  analy tes,including neutrophil counts and 
immunogenicit y;CDRS ; C-SSRS ;and vital signs will be summarized .  
Immunization history  will be summarized at baseline, and any unexpected outcomes or effects 
related to standard -of-care vaccinat ion will  be summarized.
I1F-MC-RHCD (b)Clinical Protocol Page 72
LY2439821For Period 2, Inducti on, the safety  data will  be summarized and analyzed with treatm ent 
comparisons of ixekizumab ver sus pl acebo .  
For all ixekizumab treatment periods combined (Periods 2, 3, and 4) ,safet y data will be 
summarized.
During the Post-Treatment Follow -Up Period (Period 5 ), safety data will be summariz ed.  
The categorical safet y measures will be summari zed with frequencies. The m ean change of the 
continuous safet y measu res will be summarized .  
10.4.5.1. Adverse Events
AEs are cl assified based on the Medical Dict ionary for Regulatory  Activities (MedDRA ).  A 
TEAE is defined as an event that first occurred or worsened in severit y after baseline and on or 
prior to the date of the last visit wit hin the treatm ent p eriod.  Both the date/time of the event and 
the date/time of the dose (that is, injection) are considered when determining TEAEs.  A follow-
up em ergent AE is def ined as an event that first occurred or worsened in severit y aftersubject
discontinuat ion from treatm ent.  For events that are gender -specific, the denominator and 
computati on of  the percentage will only include subject s from the given gender.  
An overall summary o f AEs will be provided for Period 2, Induction and all ixekizumab 
treatm ent peri ods combined. The AE summary includes the number and percentage of subject s 
who experienced at least 1 TEAE , TEAE sby maximum severit y, death, SAE s, TEAE srelated to 
study  drug , discont inuat ions from treatm ent due to an AE, and treatment -emergent AESI s.  
TEAE s (all, by maximum severit y), SAE s including deaths, and AEs that lead to treatment 
discontinuat ion will  be summarized and analyzed by  MedDRA system  organ class and preferred 
term.  
In addit ion to general safet y param eters, safet y inform ation on specific topi cs of  AESI s will also 
be presented.  Poten tial AESI swill be ident ified by a standardized MedDRA query or a 
Lilly -defined MedDRA preferred term list ing.
Follow-up em ergent AEs, SAE s including deaths, and AEs that lead to study  discont inuat ion will 
be summarized by MedDRA system  organ class and preferred term forPeriod 5.  
10.4.5.2. Clinical Laboratory Tests
Laboratory  assessments will be analyzed as mean changes fro m baseline and as incidence of 
treatm ent-emergent abnormal, high, or low laboratory  values.  Shift tables will be presented for 
selected parameters.
For categorical lab oratory tests: 
oTreatment -emergent abnormal value = a change from normal at all baseline visits 
to abnormal at any  time postbaseline.
For continuous lab oratory tests: 
I1F-MC-RHCD (b)Clinical Protocol Page 73
LY2439821oTreatment -emergent high value = a change from a value less than or equal to the 
high limit at all baseline visits to a value greater than the high limit at any  time 
postbaseline.
oTreatment -emergent low value = a change from a value greater than or equal to 
the low limi t at all  baseline visi ts to a value l ess than the l ow limi t at any  time 
postbaseline.
10.4.5.3. Vital Signs, Physical Findings, and Other Safety Evaluations
Vital signs will  be analyzed as mean changes from baseline and as incidence of treatm ent-
emergent abnormal values.
CDRS total scores will be analyzed as mean changes from baseline. 
C-SSRS responses will be listed by  subject and visit. Only subject s that sh ow sui cidal 
ideat ion/behavior or self -injuri ous behavi or wi thout sui cidal  intent will be displayed (i .e., if a 
subject answers are all “no” for the C -SSRS, then that subject will not be displayed).
Weight, hei ght,and tanner stage data will be summarized for every  visit.
Weight, height, and BMI data will be merged to the CDC standard growth data by  age and 
gender to compare subjects’ growth wi th the standard. 
Shift table sfor tanner stage from maximum baseline to maximum postbaseline by gender will be 
presented.
Assessment of immunogenicit y with respect to safety  will include com parison of subjects who 
experience TEAEs of systemic allergy/hypersensit ivity and of inject ion-site reacti ons and who 
also develop treatment -emergent ant i-ixekizumab ant ibody  posi tivity with subjects who 
experience the same t ypes of TEAEs but who remain treatment -emergent anti -ixekizumab 
antibody  negat ive. Anti-ixekizumab antibody  titers will also be evaluated in anti -ixekizumab 
antibody -positive subjects who experience these events.
Further analyses may  be perform ed.
10.4.6. Pharmacokinetic/Pharmacodynamic Analyses
Observed ixekizumab serum trough concentrations will be summarized by t ime point across the 
study . The PK parameters of ixekizumab in pediatric subjects will be determined using 
popul ation PK methods.  
The exposure -response relationship will be invest igated between steady -state trough 
concentrations of ixekizumab and clinically  important efficacy  measures ( e.g., sPGA an d PASI 
endpo ints) at Week 12 using graphical methods and ,if appropriate, modeling methods. If 
applicable, the potential impact of immunogenicit y on ixekizumab exposure and/or efficacy 
responses may be evaluated by  graphical  assessments, as appropriate, t o com pare drug exposure 
or efficacy responses between ADA -negat ive and ADA -positive subjects at corresponding visits 
or before and after ADA development for subjects who develop ADA. Both treatment -emergent 
I1F-MC-RHCD (b)Clinical Protocol Page 74
LY2439821only and all ADA posi tive/negat ive subjects may be evaluated.  A similar approach may be taken 
if subjects beco me neutralizing ant ibody  positive. 
Addit ional analyses m ay be performed upon receipt of the data. The data from this study  may be 
combined wit h data from previous adult studies if needed for model devel opment.
10.4.7. Other Analyses
10.4.7.1. Health Outcomes/Quality of Life Measures
The analyses of health outcome svariables for Period 2, Induction will be based on the ITT 
Population, unless otherwise specified.  T here will be no adjustment for mult iple co mpar isons.  
Table RHCD. 4includes the healt h outcom e
svariables and methods.  
Table RHCD. 4. Analyses of Health Outcome sVariable s
Health Outcome and 
Quality -of-Life 
Measure Variable Analysis
Itch NRS Improvement ≥4 for subject s who 
had a baseline Itch NRS ≥4Fisher ’sexact test with NRI
Change f rom baseline ANCOVA with LOCF
MMRM
CDLQI /DLQI Achieving CDLQI/DLQI total score 
0 or 1Fisher’s exact test with NRI
Patient’s global 
assessment of disease 
severityAchieving patient’s global 
assessment of disease severity 0 or 1Fisher ’sexact test with NRI
Abbreviations:  ANCOVA = analysis of covariance; CDLQI = Children’s Dermatology Li fe Quality Index; 
DLQI =Dermatology Life Quality Index; LOCF = last observation carried forward ; MMRM = mixed model for 
repeated measures ; NRI = nonresponder imputation; NRS = numeric rating scale.
10.4.7.2. Subgroup Analyses
Subgroup analysis will be conducted for PASI 75 and sPGA (0, 1) using the ITT Population for 
Period 2, Induction .
Subgroups to be evaluated may  include gender, age, weight, ethnicit y, regi on, geographi c regi on, 
baseline disease severit y, durati on of  disease, previous non biologicsystemic therapy , and 
previous bio logic therapy .  Detailed description sof the subgroup variables will be provided in 
the statistical analysis plan .
A logistic regressio n model with treatm ent, subgroup, and interaction of subgroup -by-treatm ent 
included as factors will be used.  The subgroup -by-treatment interacti on will be tested at the 
significance l evel of 0.10.  Treatment differences will be evaluated within each category o f the 
subgroup using the Fisher ’sexact test, regardless of whether the interaction is statist ically 
significant.  Mi ssing data will be imputed using NRI.  If any group within the subgroup is <10% 
of the total  ITT populat ion, only  summaries of the efficacy  data will  be provi ded (that is, no 
inferential testing).
I1F-MC-RHCD (b)Clinical Protocol Page 75
LY2439821Addit ional subgroup analyses on efficacy or subgroup analyses on safet y may be perform ed as 
deem ed appropri ate and necessary.
10.4.8. Interim Analyses
Two interim analyses will be conducted.
A staggered approach to enrollment by weight group will be used so that a minimum of 
15subjects 12 years of age or older and >50 kg will be enro lled and safet y evaluated for the 
initial 12 weeks of dosing before opening enrollment in the middle weight group (25 to 50 kg).  
When approximately  15 subjects have enrolled in the middle weight group and completed up to 
Week12, an analysis o f all available PK data will be conducted to confirm that exposures are 
within the range expected.  All safet y data fro m these subjects will also be analyzed at this time 
in addition to sel ect efficacy data.  Doses for the remaining sub jects in the study  will be 
confirmed based on these analyses.  Once confirmed, all weight groups will be open for 
enrollment of the remaining subjects needed to complete the study.
The first interim analysis of PK, safet y, and efficacy  data on all  subjects will be conducted after 
approximately  15 subjects in the 25 -to 50 -kg weight group have completed to Week 12.  The 
analysis will include all data available at this t ime—that is, i t will  include data from  subjects in 
both wei ght groups who have enro lled at the time of the interim.  The analysis o f the data will be 
conducted by  stati sticians and PK/PD scient ists external to the study  team  (stati stical assessment 
center).  The statist ical assessment center will provide the analyses to a DMC consist ing of 
memb ers external to Lilly .  The DMC will  recommend whether changes to weight -based dosing 
are necessary  based on the analysis.  This committee will consist of a minimum of 3 members 
including a physician wit h an expertise in dermatology , a stati stician, and an additional 
clinician(s) or PK/PD expert.  No member of the DMC may have contact with study  sites.  Only 
the DMC i s authorized to evaluate unblinded interim efficacy and safet y analyses.  Study  sites 
will receive informat ion about interim result s ONLY if t hey need to know for the safet y of 
theirsubjects.
Study  sites will receive informat ion about interim results ONLY if they need to know for the 
safet y of their subjects.  
The second interim database lock and unblinding will occur and the analysis will be performed at 
the time (that is, a cutoff date) the last subject completes Study  Period 2, Induction (Week 12) or 
ETV.  This interim database lock will include all data collected by the cutoff date including 
follow
-up data fro m subjects that have begun Peri ods 3, 4, or 5.  Because the study  will still be 
ongoing at the time o f this database l ock, the analysis will be referred to as an interim analysis.  
This interim analysis includes the final analysis for the Double -Blind Treatm ent Induction Period 
(Peri od2, Induction )of the study; therefore, there is no alpha adjustment due to this interim 
analysis.  The DMC is not needed for this interim analysis.
Addit ional analyses and snapshots of study  data may  be performed during and/or after 
completion of Period 3 and/or Period 4 to fulfill the need for regulatory interactions or 
publicat ion purposes.
I1F-MC-RHCD (b)Clinical Protocol Page 76
LY2439821Enrollment of each geographic region will be closely mo nitored.  If 120 subjects from the United 
States and Canada co mplete the 12 -week Double -Blind Rando mized Period and if other regions 
are behind in reaching their enro llment goal, an addit ional interim analysis may  be conducted to 
include only  the subjects from  the Uni ted States and Canada to m eet the US submissio n timeline.  
The DMC is not needed for this interim an alysis.  The details will be documented in the 
unblinding plan and the statist ical analysis plan.  A final database lock will occur after the Post -
Treatment Follow -Up Peri od is completed.
Unblinding details are specified in the unblinding plan.
I1F-MC-RHCD (b)Clinical Protocol Page 77
LY243982111. References
Basra MK, Fenech R, Gat t RM, Salek MS, Finlay AY. The d ermatology life qualit y index 1994 -
2007: a comprehensive review of validat ion data and clinical result s. Br J Dermatol . 
2008;159(5):997 -1035.
Bronckers IM, Paller AS, van Geel MJ, van de Kerkho f PC, Se yger MM. Psori asis in children 
and adolescents: diagnosis, management and comorbidi ties. Pediatr Drugs .2015;17 (5):373-
384.
[CDC ]Centers for Disease Control and Prevent ion resources page . 
National Center for Health 
Statistics. Data table of weight -for-age charts. Available at:
http://www.cdc.gov/growthcharts/ht ml_charts/wtage.htm. Accessed October 20, 2016.
[C-SSRS] Columbia –Suici deSeverit y Rating Scale web site. Available at: 
http://www.c ssrs.columbia.edu. Accessed January  13, 2016 .
De Jager ME, Van de Kerkho f PC, De Jong EM, Sey ger MM. Epidemi ology and prescribed 
treatm ents in childhood psoriasis: a survey  among medical professio nals. J Dermatolog Treat.
2009;20(5):254 -
258.
Diggle PJ, L iang KY, Zeger SL. Analysis o f longitudinal d ata. Oxford: Clarendon Press; 1994.
[EMEA] European Medicines Agency . Committee for Medicinal  Products for Human Use 
(CHMP). Guideline on clinical invest igation of medi cinal products indicated for the treatment 
of psori asis. November 18, 2004; CHMP/EWP/2454/02 corr . Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library /Scient ific_guideline/2009/09/WC50
0003329.pdf . Accessed October 19, 2016.
Fredriksson T, Pettersson U. Severe psoriasis –oral therapy  with a new retinoid. Dermatologica. 
1978;157(4):238 -244.
Gelfand JM, Weinstein R, Porter SB, Niemann AL, Berlin JA, Margolis DJ. Prevalence and 
treatm ent of psoriasis in the United Kingdo m: a populat ion-based study . Arch Dermatol .
2005;141(12):1 537-1541.
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball 
SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun 
OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL ;UNCOVER -1 Study  Group ;UNCOVER -
2 
Study Group ;UNCOVER -3 Study  Group. Phase 3 trials o f ixekizumab in moderate -to-severe 
plaque psori asis. N Engl J Med . 2016;375(4):345 -356.
Griffit hs CE, Rei ch K, Lebwohl M, van de Kerkhof P, Paul  C, Menter A, Cameron GS, Erickson
J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nicko loff BJ, Papp 
K
;UNCOVER -2 and UNCOVER -3 invest igators. Com parison of ixekizumab wit h etanercept 
or placebo in m oderate -to-severe psoriasis (UNCOVER -2 and UNCOVER -3): results from 
two phase 3 rando mised trials. Lancet . 2015;386(9993):541-551.
Happel KI, Zheng M, Young E, Quinton LJ, Lockhart E, Ramsay AJ, Shellito JE, Schurr JR, 
Bagby  GJ, Nel son S, Kolls JK . Cutting edge: rol es of t oll-like receptor 4 and IL -23 in IL -17 
expressio n in response to Klebsiella pneum oniae infect ion. J Immunol . 2003;170(9):4432-
4436.
I1F-MC-RHCD (b)Clinical Protocol Page 78
LY2439821Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of int erleukin- 17A for systemic 
anti-Candida albicans host defense in mice. J Infect Dis . 2004;190(3):624- 631. 
Lewis -Jones MS, Finlay AY. The Children’s Dermatology  Life Qualit y Index (CDLQI): initial 
validat ion and practical use. Br J Dermatol .1995;132 (6):942- 949.
Mayes TL, Bernstein IH, Haley CL, Kennard BD, Emslie GJ. Psychometric properti es of the 
Children's D epressi on Rating Scale -Revised in adolescents . J Child Adolesc 
Psychopharmacol. 2010;20(6):513 -
516.
Milner JD, Brenchly JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, 
Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O’Shea J, Holland SM, Paul WE, Douek 
DC. Impaired T(H)17 cell differentiation in subjects with autosomal do minant hyper -IgE 
syndro me.Nature . 2008;452(7188):773-776.
Napolitano M, Megna M, Balato A, Ay ala F, Lembo S, Villani A, Balato N. Sy stemic treatment 
of pedi atric psoriasis: a review. Dermatol Ther (Heidelb) .2016;6 (2):125-142.
National Inst itutes of Healt h. The Fourth Report on The Diagnosis, Evaluat ion, and Treatment of 
High Bl ood Pressure in Children and Adolescents. Revised May 2005. Available at: 
https://www.nhlbi.nih.gov/files/docs/resources/heart/hbp_ped.pdf. Accessed Mar 20, 2017.
Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classificat ion Algorithm of 
Suicide Assessment (C -CASA): classificat ion of sui cidal events in the FDA’s pe diatri c 
suicidal risk analysis of ant idepressants. Am J Pyschiatry . 2007;164(7) :1035 -1043.
Poznanski EO , Mokros HB. Children's depressio n rating scale, revised (CDRS -R). Los Angeles: 
Western Psy chological Services ; 1996 .
Puig, L. PASI90 response: the new s tandard in therapeutic efficacy for psoriasis. J Eur Acad 
Dermatol Venereol . 2015; 29: 645 -648. 
Rasmussen AR, Wohlfahrt -Veje C, Tefre de Renzy -Mart in K, Hagen CP, Tinggaard J, 
Mouri tsen A, Mieri tz MG, Main KM. Validit y of self-assessment of pubertal matura tion.  
Pediatrics .2015;135(1):86 -93.
Salek MS, Jung S, Brincat- Ruffini LA, Mac Farlane L, Lewi s-Jones MS, Basra MK, Finlay  AY. 
Clinical experience and psycho metric properti es of the Children’s Dermatology  Life Quali ty 
Index (CDLQI), 1995 -2012. Br J Dermatol .2013;169 (4):734-759.
Van Voorhees A, Feldman SR, Koo JYM, Lebwohl MG, Menter A. The psoriasis and psoriat ic 
arthri tis pocket gui de. Nati onal Psori asis Foundation. 2009. Available at: 
https://www.psoriasis.org/sites/default/files/accessing -healt h
-
care/FY10_Pocket_Guide_WEB.pdf. Accessed November 18, 2016. 
Waters A, Sandhu D, Beattie P, Ezughah F, Lewis -Jones S. Severit y stratificat ion of Children’s 
Derm atology Life Qualit y Index (CDLQI) scores [abstract] . Br J Dermatol .
2010;163( suppl 1):121.
I1F-MC-RHCD (b)Clinical Protocol Page 79
LY243982112. Appendices
I1F-MC-RHCD (b)Clinical Protocol Page 80
LY2439821Appendix 1. Abbreviations and Definitions
Term Definition
ADA antidrugantibody
AE adverse event:  Any untoward medical occurrence in a subject or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or
not related to the medicinal (investigational) product.
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
BCG Bacillus Calmette -Guérin
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the subject is not, or vice versa, or when the Sponsor is aware of the 
treatment but the investigator and/his staff and the subject are not.
A double -blind study is one in which neither the subject nor any of the investigator or 
Sponsor staff who are involved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received.
BP blood pressure
BSA body surface area
CDC Centers for Disease Control and Prevention
CDLQI Children’s Dermatology Life Quality Index
CDRS Children’s Depression Rating Scale
CEC Clinical Events Committee
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality , purity , durability , reliability , safety  or effectiveness, or 
performance of a drug or drug delivery system.
CRF case report form
CRP clinical research physician : Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
I1F-MC-RHCD (b)Clinical Protocol Page 81
LY2439821CSR clinical study report
C-SSRS Columbia –Suicide Severity Rating Scale
DLQI Dermatology Life Quality Index
DMC data monitoring committee
ECG electrocardiogram
eCRF electronic case report form
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
enter Subjects entered into a study are those who sign the assent/informed consent form 
directly or through their legally acceptable representatives.
ERB ethical review board
ETV Early  Termination Visit
EU European Union
GCP good clinical practice
HBcAb+ positive for anti -hepatitis B core antibody
HBsAg+ positive for hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
ITT intent to treat:  The principle that asserts that the effect of a treatment policy can be best 
assessed by evaluating on the basis of the intention to treat a subject (that is, the planned 
treatment regimen) rather than the actual treatment given.  It has the consequence that 
subjects allocated to a treatment group should be followed up, assessed, and analyzed as 
members of that group irrespective of their compliance to the planned course of 
treatment.
IWRS interactive web -
response sy stem
Lilly Eli Lilly and Company
I1F-MC-RHCD (b)Clinical Protocol Page 82
LY2439821MedDRA Medical Dictionary for Regulatory Activities
MMRM mixed model for repeated measures
NK natural killer
NRI nonresponder imputation
PASI Psoriasis Area and Severity Index
PASI 100 a 100% improvement from baseline in PASI score
PASI 75 at least a 75% improvement from baseline in PASI score
PASI 90 at least a 90% improvement from baseline in PASI score
PD pharmacodynamic(s)
PIP Pediatric Investigation Plan
PK pharmacokinetic(s)
PPASI Palmoplantar Psoriasis Severity Index
PPD purified protein derivative
Ps psoriasis
PsA psoriatic arthritis
PSSI Psoriasis Scalp Severity Index
Q4W every 4 weeks
RBC red blood cell
SAE serious adverse event
SC subcutaneous(ly)
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.  
sPGA static Phys ician’s Global Assessment
study drug A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical study, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
SUSAR suspected unexpected serious adverse reaction
TB tuberculosis
I1F-MC-RHCD (b)Clinical Protocol Page 83
LY2439821TBL total bilirubin level
TEAE treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, which and does not necessarily have to h ave a causal 
relatio nship with this treatment.
ULN upper limit of normal
USA United States of America
WBC white blood cell
I1F-MC-RHCD (b)Clinical Protocol Page 84
LY2439821Appendix 2. Clinical Laboratory  Tests 
Clinical Laboratory Tests
Abbreviations:  GGT = gamma -glutamyl transferase; IgA = immunoglobulin A; IgG = immunoglobulin G; 
IgM =immunoglobulin M; NK = natural killer; PK=pharmacokinetic ; PPD = purified p rotein derivative; 
RBC =red blood cell; TB=tuberculosis ; WBC =white blood cell.
aAssay ed by Lilly -designated laboratory.
bResults will be confirmed by the central laboratory at the time of initial testing .
cSerum pregnancy test will be done at Visit 1 only and will be performed centrally .  Subjects will undergo urine 
pregnancy testing at the clinic on a monthly basis during scheduled visits through Week 108 .  Additional urine 
pregnancy testing can be performed at the investigator’s discretion.
dAs appropriate for age.Hematology a,b Clinical Chemistry a-c
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume Bicarbonate
Mean cell hemoglobin concentration Chloride
Leukocytes (WBC) Phospho rus
Neutrophils, segmented Total bilirubin
Neutrophils, juvenile (bands) Direct bilirubin
Lymphocy tes Alkaline phosphatase
Monocytes Alanine aminotransferase
Eosinophils Aspartate aminotransferase
Basophils Blood urea nitrogen
Platelets Creatinine
Uric acid
Calcium
Random blood glucose
Albumin
Urinalysis a Cholesterol (total)
Specific gravity Total protein
pH Triglycerides
Protein GGT
Glucose
Ketones Pregnancy Test (females only, serum and urine) c,d
Blood Other Tests a
Urobilinogen Human immunodeficiency virus antibody
Bilirubin Hepatitis B virus DNA
Nitrite Hepatitis B surface antigen (HBsAg)
Urine creatinine Hepatitis B surface antibody
Leukocyte esterase Hepatitis B core antibody
Color Hepatitis C virus
Serum immunoglobulins (IgA, IgG, and IgM)
Cell Flow Cytometry PPD/QuantiFERON® -TB Gold
Immunogenicity testing
B cells, T cells, CD4+ T cells, CD8+ T cells, NK cells PK sample
I1F-MC-RHCD (b)Clinical Protocol Page 85
LY2439821Appendix 3. Study  Governance Considerations
Appendix 3.1.Regulatory and Ethical Considerations, Including the 
Informed Consent Process
Appendix 3.1.1 .Informed Consent
The invest igator is responsible for ensuring:
that the subject understands the potential risks and benefits of part icipating in 
the study
that informed consent is given by each subject or legal representative.  This 
includes obtaining the appropriate signatures and dates on the informed 
consent form (ICF) prior to th e performance of any protocol procedures and 
prior to the administration o f study  drug
answering any quest ions the subject may  have throughout the study  and 
sharing in a t imely manner any  new informat ion that m ay be relevant to the 
subject’s willingness to continue his or her participation in the study .
A legal representative must give informed consent for a child to participate in this study.  In 
addition to inform ed consent given by the legal representative, the child may  be requi red to give 
docum ented as sent, if capable.
Appendix 3.1.2. Ethical Review
The invest igator or an appropriate local representative must give assurance that the ethical 
review board (ERB) was properly  consti tuted and convened as required by Internat ional Council 
for Harm onisat ion (ICH) gui delines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF and Assent Form must be provided 
to Lilly  before the study  may begin at the invest igative site(s).  Lilly or its representatives must 
approve the ICF, including any changes made by the ERBs, before it is used at the invest igative 
site(s).  All  ICFs must be com pliant wi th the ICH gui deline on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
current IBand updates during the course of the study
ICFand Assent Form
relevant curri cula vi tae
Appendix 3.1.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
I1F-MC-RHCD (b)Clinical Protocol Page 86
LY2439821consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl arationof Helsinki  and Council forInternational Organizati onsof
Medical Sciences Internat ional Ethi cal Guidelines
applicable ICH good clinical practice ( GCP ) guidelines
applicable laws and regulations
Some of the obligat ions of the Sponsor will be assigned to a third party .
Appendix 3.1.4. Investigator Information
Physicians with a specialt y in dermatol ogy or pediatri c derm atologywill participate as 
investigators in this clinical study .
Appendix 3.1.5. Protocol Signatures
The Sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of 
thestudy .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Appendix 3.1.6. Final Report Signature
The clinical study  report ( CSR )coordinating investigator will sign the final CSR for this study , 
indicat ing agreement that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
The Sponsor’s responsible medical officer and statist ician will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
Appendi x 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
Conduct Sponsor start -up training to instruct the investigators and study 
coordinators.  This training will give instruction on the proto col, the complet ion 
of the CRFs, and study  procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  
mail, tel ephone, and/or fax
review and evaluate case report form ( CRF)data and use standard computer edits 
to detect errors in data collect ion
conduct a qualit y review of the database
I1F-MC-RHCD (b)Clinical Protocol Page 87
LY2439821In addit ion, Lilly or its representatives will periodically check a sample of the subject data 
recorded against source documents at the study site.  The study  may be audi ted by  Lilly or i ts 
representatives and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laborat ory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the Sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Appendix 3.2.1. Data Capture System
An electronic data capture sy stem  will be used in this study .  The study  site maintains a separate 
source for the data entered by  the si te into the Sponsor -provided electronic data capture system.
Any data for which paper documentation provided by the subject will serve as the source 
docum ent will be i dentified and documented by  each si te in that si te’s study  file.  Paper 
docum entati on provi ded by  thesubject may include, for example, a paper diary to collect patient -
reported outcome measures ( e.g., a rating scale), a d aily dosing schedule, or an event diary .
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
Appendix 3.3. Study and Site Closure
Appendix 3.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I1F-MC-RHCD (b)Clinical Protocol Page 88
LY2439821Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent Abnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th subject s in consultation with the Lilly , or i ts desi gnee, clinical 
research physician .
Hepatic Monitoring Tests
Hepatic hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic coagulation a
RBC Prothrombin time
WBC Prothrombin time, INR
Neutrophils, segmented
Lymphocy tes Hepatic serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic chemistry Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti nuclear antibody a
AST
GGT Alkaline phosphatase isoenzymes a
CPK
Anti –smooth muscle antibody (or anti - actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; IgG= immunoglobulin G; IgM= immunoglobulin M; 
INR =international normalized ratio; RBC = red blood cell; WBC = white blood cell.
aAssay ed by Lilly -designated or local l aboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I1F-MC-RHCD (b)Clinical Protocol Page 89
LY2439821Appendix 5. Blood Pressure Levels for Children 
with Median Height by  Age and Gender
Boy Girl
Age 
(Year)Hypertension 
StageSystolic BP 
(mmHg)
(supine or sitting 
–forearm at 
heart level)Diastolic BP 
(mmHg)
(supine or sitting 
–forearm at 
heart level)Systolic BP 
(mmHg)
(supine or sitting 
–forearm at 
heart level)Diastolic BP 
(mmHg)
(supine or sitting –
forearm at heart 
level)
6Prehypertension ≥110 and <114 ≥70 and <74 ≥108 and <111 ≥70 and <74
Stage 1 ≥114 and <126 ≥74 and <87 ≥111 and <124 ≥74 and <86
Stage 2 ≥126 ≥87 ≥124 ≥86
7Prehypertension ≥111 and <115 ≥72 and <76 ≥109 and <113 ≥71 and <75
Stage 1 ≥115 and <127 ≥76 and <89 ≥113 and <125 ≥75 and <87
Stage 2 ≥127 ≥89 ≥125 ≥87
8Prehypertension ≥112 and <116 ≥73 and <78 ≥111 and <115 ≥72 and <76
Stage 1 ≥116 and <128 ≥78 and <91 ≥115 and <127 ≥76 and <88
Stage 2 ≥128 ≥91 ≥127 ≥88
9Prehypertension ≥114 and <118 ≥75 and <79 ≥113 and <117 ≥73 and <77
Stage 1 ≥118 and <130 ≥79 and <92 ≥117 and <129 ≥77 and <89
Stage 2 ≥130 ≥92 ≥129 ≥89
10Prehypertension ≥115 and <119 ≥75 and <80 ≥115 and <119 ≥74 and <78
Stage 1 ≥119 and <132 ≥80 and <93 ≥119 and <131 ≥78 and <91
Stage 2 ≥132 ≥93 ≥131 ≥91
11Prehypertension ≥117 and <121 ≥76 and <80 ≥117 and <121 ≥75 and <79
Stage 1 ≥121 and <134 ≥80 and <93 ≥121 and <133 ≥79 and <92
Stage 2 ≥134 ≥93 ≥133 ≥92
12Prehypertension ≥120 and <123 ≥76 and <81 ≥119 and <123 ≥76 and <80
Stage 1 ≥123 and < 136 ≥81 and <94 ≥123 and <135 ≥80 and <93
Stage 2 ≥136 ≥94 ≥135 ≥93
13Prehypertension ≥120 and <126 ≥77 and <81 ≥120 and <124 ≥77 and <81
Stage 1 ≥126 and <138 ≥81 and <94 ≥124 and <137 ≥81 and <94
Stage 2 ≥138 ≥94 ≥137 ≥94
14Prehypertension ≥120 and <128 ≥78 and <82 ≥120 and <126 ≥78 and <82
Stage 1 ≥128 and <141 ≥82 and <95 ≥126 and <138 ≥82 and <95
Stage 2 ≥141 ≥95 ≥138 ≥95
15Prehypertension ≥120 and <131 ≥79 and <83 ≥120 and <127 ≥79 and <83
Stage 1 ≥131 and <143 ≥83 and <96 ≥127 and < 139 ≥83 and <96
Stage 2 ≥143 ≥96 ≥139 ≥96
16Prehypertension ≥120 and <134 ≥80 and <84 ≥120 and <128 ≥80 and <84
Stage 1 ≥134 and <146 ≥84 and <97 ≥128 and <140 ≥84 and <96
Stage 2 ≥146 ≥97 ≥140 ≥96
I1F-MC-RHCD (b)Clinical Protocol Page 90
LY2439821Abbreviations:  BP = blood pressure; mmHg = millimeters of mercury.
Source: [NIH] The Fourth report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children 
and Adolescents. Revised May 2005 .17Prehypertension ≥120 and <136 ≥80 and <87 ≥120 and <129 ≥80 and <84
Stage 1 ≥136 and <148 ≥87 and <99 ≥129 and <141 ≥84 and <96
Stage 2 ≥148 ≥99 ≥141 ≥96
I1F-MC-RHCD (b)Clinical Protocol Page 91
LY2439821Appendix 6. Protocol A mendment I1F -MC-RHCD( b) 
Summary :  Multicenter, Double -Blind, Randomized, 
Placebo- Controlled Study  to Evaluate Safety , Tolerability
and Efficacy  of Ixekizumab in Patients from 6 to Less 
than 18 Years of A ge with Moderate -to-Severe Plaque 
Psoriasis
Overview
Protocol  I1F-MC-RHCD (a)Multicenter, Doubl e-Blind, Rando mized, Placebo -Controlled Study  
to Evaluate Safety  and Efficacy  of Ixekizumab in Patients fro m 6 toLess than 18 Years of Age 
with Moderate -to-Severe Plaque Psoriasis, has been amended.  The new protocol is indicated by  
amendment ( b) and will be used to conduct the study  in place of any preceding version o f the 
protocol .
The m ajor changes and rati onale for the changes made to this protocol are as fo llows:
Addit ion of language that allows for additional int erim analysis 
Updated l anguage so that si tes are not required to take oral body  temperature
Clarified that when patient is at tanner stage score 5, th e site does not need to complete 
the scale wit h the patient any  longer
Clarified the timing of Bone age imaging so that it is acceptable if this test is done at 
either Visi t 1 or 2 and if it i s done in the last 6 months then it does not need to be repeated
Clarified that vi tal signs need to be taken at least 30 mins before injection instead of 
approximately  30 mins before inject ion
Updated the exclusio n criterion so that pati ents wi th lymphoproliferat ive and other 
malignant disorders are excluded fro m study participat ion unless it is ruled out by  biopsy
Updated the exclusio n criterion that specifies the time frame of receiving other therapies 
to state that these time frames are with respect to screening time
Corrected the tit le of Appendix 6 .
Removedreference to QIDS on the list of reasons for discont inuat ion
Correct edthe wording about washout which says screening and baseline which is not 
consistent in the protocol 
Update dinclusio n criteria language that ‘Lilly  empl oyees’ cannot participate 
Removedstatement that the inject ion cannot be done over the plaques 
I1F-MC-RHCD (b)Clinical Protocol Page 92
LY2439821Updat edthat Ixekizumab is current ly approved for PsA. Addit ionally it i s also approved 
in Japan for PsO and Pustular Ps and Ery throdermic PsO .
I1F-MC-RHCD (b)Clinical Protocol Page 93
LY2439821Revised Protocol Sections
Note: Deletions have been ident ified by strikethroughs .
Addit ions have been identified by  the use of underscore .
1. Synopsis
Rationale:  
There is an unmet medical need for effective and safe therapies for children and adolescents with 
moderate -to-severe plaque psoriasis (Ps).  Ixekizumab has been approved for the treatment of adults with moderate -
to-severe plaque Ps and psoriatic arthritis ( PsA)in a number of countries globally.  It has also been approved for 
adults with psoriatic arthritis (PsA) Pustular Ps and Ery throdermic Ps in Japan and is currently being studied in 
adults with axial spondyloarthritis.  
Interim Analyses :
Two  interim analyses will be conducted.  The first interim analysis o f PK, safet y, and select 
efficacy  data on all  subjects will be co nducted after approximately  15 subjects have com pleted to 
Week 12 in the 25 -to 50 -kg weight group.  A second interim analysis will be performed at the 
time (that is, a cutoff date) the last subject completes Study  Period 2, Inducti on (Week 12) or at 
the Early Terminat ion Visit.  Addit ional analyses and snapshots of study  data m ay be performed 
during and/or after complet ion of Period 3 and/or Period 4 to fulfill the need for regulatory  
interact ions or publicat ion purposes.   
I1F-MC-RHCD (b)Clinical Protocol Page 103
LY2439821Schedule of Activities, Protocol I1F-MC-RHCD
Abbreviations:   AE = adverse event; AESI = adverse event of special interest; ALT = alanine aminotransferase; AST = aspartate aminotransferas e; BP = blood 
pressure; BSA = body surface area; CDLQI = Children's Dermatology Life Quality Index; d =days; DLQI = Dermatology Li fe Quality Index; 
ECG =electrocardiogram; ETV = Early Termination Visit; HBcAb+ = positive for anti -hepatitis B core antibody; HBsAb = hepatitis B surface antibody; 
HBV = hepatitis B virus; HCV = hepatitis C virus; HIV =human immunodeficiency virus; IgA = immunoglobulin A; IgG = immunoglobulin G; 
IgM =immunoglobulin M; IXE =ixekizumab (LY2439821); LV= last visit; NAPSI = Nail Psoriasis Severity Index; NK =natural killer; NRS = numeric 
rating scale; PASI = Psoriasis Area and Severity Index; PPASI = Palm oplantar Psoriasis Area and Severity Index; PPD =purified protein derivative; 
PK=pharmacokinetics; PSSI = Psoriasis Scalp Severity Index; Q4W = every 4 weeks; SC = subcutaneous; sPGA = static Physician’s Gl obal Assessment; 
TB = tuberculosis; ULN = upper limit of normal; V = study visit; W = study week.
aThe parent or legal guardian will sign the informed consent form, and the subject will sign the assent form prior to any stud y assessments, examinations, or 
procedures being performed.  An informed conse nt form should be signed by the subject when the legal age is reached as determined by the country 
regulations.  
bComplete medical history, including TB exposure.
cDemographics include recording the full date of birth, sex, and ethnicity. In countries w here we are not allowed to collect the full date of birth, (day, month, 
and y ear) we will make country specific adjustments to collect only month and year. 
dOne complete physical examination (excluding pelvic, rectal, and breast examinations) will be per formed at screening.  All physical examinations throughout 
the study  should include a symptom -directed physical as well as an examination of heart, lungs, and abdomen and a visual examination of the skin, including 
genitals.  
eHabits include recording of caffeine, alcohol, and tobacco consumption.  This assessment is only required for subjects 12 years of age or older.  
fSubjects who test positive for latent TB at screening may be rescreened following appropriate treatment.  Additionally, subje cts who do not qualify at 
screening under Exclusion Criterion [14] (active or recent infection) or Exclusion Criterion [16] ( oral body temperature ≥38°C [100.5°F]) may be rescreened 
1 time.
gAt baseline (Week 0), BP and pulse should be measured approximately at least30 minutes pre -and postinjection.  BP and pulse should be measured pre -and 
postinjection at the other visits.  
h Inflammator y bowel disease will be assessed as an AESI.  See Section 9.2.2 for a list of all AESIs.  
i The study drug will be prepared by a trained clinical staff member who will be an unblinded member.  Site staff will reco rd information in th
e Study Drug 
Administration Logs, including the date, time, and anatomical location of administration of study drug (for treatment complia nce); sy ringe number; who 
prepared and administered the study drug; and the reason if study drug was not fully administered.
jSubjects should remain under observation for at least 1 hour after dosing at Week 0 (Visit 2), Week 4 (Visit 4), Week 8 (Visit 6), Week 12(Visit 7), and 
Week 16 (Visit 8) to monitor for safety.  For subsequent injections during the study, and if no problems occurred with that injection, subje cts will be observed 
for 15 minutes following injection.
I1F-MC-RHCD (b)Clinical Protocol Page 104
LY2439821kSubjects receiving ixekizumab 20 mg or 40 mg will receive 1 SC injection of ixekizumab at Week 0 (Visit 2) and 1 SC injection of ixekizumab Q4W at 
Weeks 4 and 8.  Subjects receiving ixekizumab 80 mg will receive 2 SC injections of ixekizumab at Week 0 (Visit 2) and 1 SC i njection of ixekizumab Q4W 
at Weeks 4 and 8.  
Subjects receiving placebo for ixekizumab 20 mg or 40 mg will receive 1 SC injection of placebo at Week 0 (Visit 2) and 1 SC injection of placebo Q4W at 
Weeks 4 and 8.  Subjects receiving placebo for ixekizumab 80 mg will receive 2 SC injections of placebo at Week 0 (Visit 2) and 1 SC injection of placebo 
Q4W at Weeks 4 and 8.  
lIf the subject has nail psoriasis, scalp psoriasis or palmoplantar psoriasis at baseline, then the NAPSI, PSSI or PPASI, resp ectively, will be administered a t 
subsequent visits, as indicated in the Schedule of Activities.
mAt tanner stage score 5, the site does notneed to complete the scale with the subject any longer.
m nA Self -Harm Follow -Up Form must be completed for each discrete event identified on the Self-Harm Supplement Form.
n oQuantiFERON ®-TB Gold test is preferred.  For those subjects administered a PPD test, the subject will visit the site between 48 to 72 hours after PPD 
placement for the PPD read.  
o pA chest x -ray will be taken at screening , unless one has been obtained within the past 6 months (provided the x -ray and/o r report are available for review).  In 
Germany, a chest x -ray has to be performed within 6 months prior to signing informed consent indicating no evidence of TB.
qFor the Bo ne age imaging at Visit 2, it is acceptable if the test is performed at Visit 1. In case test is performed in the last 6 mont hs, it does not need to be 
repeated at Visit 2.
p rSubjects must be supine for a minimum of 5 minutes before ECG collection and re main supine during ECG collection.  ECGs may be obtained at additional 
times, when deemed clinically necessary.  
q sSubjects who are HBcAb+, HBsAb+, and HBV DNA –at screening will be tested for HBsAb levels at baseline, at 12 -week intervals thereafter, a nd at the 
ETV, if applicable.  Subjects who meet these criteria for HBsAb monitoring will be identified by the central laboratory.  Sub jects whose HBsAb levels are 
<200 mIU/mL at any postscreening visit will be tested for HBV DNA.  Any enrolled subject who is HBcAb+, regardless of HBsAb status or level, and who 
experiences elevated ALT or AST >3 times ULN must undergo HBV DNA testing.
r tTo be performed for females of childbearing potential only (ages 12 and older or younger subjects per investigator asses sment of full sexual maturity).  Serum 
pregnancy test will be done at Visit 1 only and will be performed centrally.  Subjects will undergo urine pregnancy testing a t the clinic on a monthly basis 
during scheduled visits through Week 108.  Additional urine pregnancy testing can be performed at the investigator’s discretion.  Subjects determined to be 
pregnant will be discontinued from treatment and will no longer be administered study drug.
s uWhere collection is allowed by local regulations.
t vImmunogenicity samples may also be analyzed for ixekizumab serum concentration to facilitate in the interpretation of the imm unogenicity data.  In addition, 
a blood sample will be collected, when possible, for any subject who experiences a potential system ic allergic/hypersensitivity reaction during the study as 
judged by the investigator.  At visits where study drug will be administered, immunogenicity samples will be collected prior to administration of study drug.  
Ideally , samples will be taken at appro ximately  the same time for each collection.
u wAt visits where study drug will be administered, PK samples will be collected prior to administration of study drug.
v xAll subjects receiving study drug must enter into Period 5 and complete through Visit 8 02.  Subjects may be followed beyond Visit 802 for continued 
monitoring of their neutrophil counts if determined by the Sponsor/investigator that additional monitoring is needed.  If a s ubject discontinues study drug 
early , the subject will complete the ET V and then enter the Post -Treatment Follow -Up Period (Period 5).
w yThis visit will only occur if a subject’s neutrophil counts have not returned to the defined criteria.
I1F-MC-RHCD (b)Clinical Protocol Page 105
LY24398213.1 Study Rationale
There i s an unmet m edical need for effect ive and sa fe therapies for children and adolescents with 
moderate -to-severe plaque Ps.  Ixekizumab has been approved for the treatment of adults with 
moderate -to-severe plaque Ps  and PsA in a number of countries globally.  It is current ly being 
studi ed in adult s with PsA in the United States and European Unio n, has already has also been 
approved for adults with PsA in Japan with Pustu larPs and Ery throdermic Ps in Japan , and is 
currently being studied in adults wit h axial spondyloarthrit is.  This study  is part of th e European 
PIP and USA Pediatric Study  Plan, and i t is intended to investigate the safet y, efficacy, and PK 
of ixekizumab in pediatric subjects (children and adolescents).  This study  will assess specific 
response in the Pediatric Populat ion.  The risks an d benefit s in the Pediatric Populat ion are 
expected to be similar to those in adults with plaque Ps.  There is no specific difference in the 
mechanism o f the disease; therefore, no difference in the safet y profile is expected between 
adults, adol escents, a nd children.  
3.2. Back ground
Pediatric pl aque Ps affects approximately 1% of children and adolescents globally  (Gelfand et al . 
2005; Napo litano et al . 2016).  It i s estimated that 35% to 50% of adults with psoriasis developed 
their disease before 20 y ears of age (De Jager et al. 2009).  In a report by  Gelfand et al . (2005), 
the prevalence of plaque Ps in children in the Unit ed Kingdo m was 0.55% for those aged 0 to 9 
years and 1.37% for those aged 10 to 19 years.  Pediatric plaque Ps is especially burdenso me 
because it often presents on the face and scalp, as well as other highly  visible areas.  Nonbio logic 
topical therapies have been the mainstay  of treatment due to l ack of approved therapies for 
plaque Ps in children.  Currently , there are few systemic th erapies for pediatric plaque Ps, and 
most have significant side effects or are not as effective as desired (Bronckers et al. 2015).
Current ly, there is an unmet medical need for effective and safe therapies for children and 
adolescents wi th moderate -to-severe psori asis.  Both the PIP and Pediatric Study  Plan will  focus 
on pedi atric subjects wi th moderate -to-severe plaque Ps fro m 6 to <18 y ears of age.
This study  will explore specific response in the Pediatric Populat ion.  The risks and benefits in 
the Pediatric Population are expected to be similar to those in adults wit h plaque Ps.  There i s no 
specific difference in the mechanism o f the disease; there fore, no difference in the safet y profile 
is expected between adults, adolescents, and children.  
6.2 Exclusion Criteria
[16] have a noral body  temperature ≥38°C (100.5°F) at baseline (Week 0; Visit 2); these 
subjects may  be rescreened (1 time) ≥4 weeks a fter documented resolut ion of elevated 
temperature
[18] subjects wi th a known history  of malignancy; lymphoproliferat ive disease, including 
lympho ma; or si gns and symptom s suggest ive o f possible lymphoproliferat ive disease, such as 
lymphadenopathy  and/or spl enomegaly unless  ruled out by  biopsy
I1F-MC-RHCD (b)Clinical Protocol Page 106
LY2439821[34] have receiv ed other therapi es wi thin the specified time frames prior to screening (see 
below) below :
adalimumab and infliximab 60 days, abatacept 90 days, anakinra 7 day s, or any  other 
biologic disease -modifying ant irheumat ic drug 5 half -lives prior to baseline
system ic therapy  for pl aque Ps and PsA (other than above, e.g., methotrexate, 
cyclosporine) or phototherapy  (e.g., photochem otherapy  [psoralen pl us ul traviolet A]) in 
the previous 4 weeks
any invest igational drugs in the previous 4 weeks or 5 half -lives, whichev er is longer
ultraviolet-
A therapy , ultraviolet-B therapy , and topi cal treatments (except on face, scalp, and genital 
area during screening) in the previous 4 weeks
[43] are em ployees of Lilly or its designee or are emplo yees of third party  organizat ions 
involved in the study
7.1 Treatments Administered
This study  involves a comparison of ixekizumab administered by SC inject ion with placebo.  
The study  drug shoul d be at room  temperature when injected.  Possible injection sites include the 
abdo men, thi gh, a nd upper arm  (using the arm contralateral for blood samples for PK).  The 
inject ion site should preferably not be in a psoriat ic lesion and shoul d be rotated to another area 
for subsequent doses at the same visit.
7.8.3 Permanent Discontinuation from Study Treatment
The patient, at any  time during the study , scores a ≥5 for Item  133 for Item 12 (Thoughts 
of Death or Sui cide) on the QIDS SR16 CDRS -R
-OR
develops active suicidal ideat ion with som e intent to act with or without a specific plan 
(yes to questi on4 or 5 on the “Suicidal Ideat ion” portion of the Columbia –Suicide 
Severit y Rating Scale [C -SSRS])
-OR
develops suicide -related behaviors as recorded on the C -SSRS.
10.4.2 Analysis Methods
The primary  analyses method for categorical data comparison between treatm ents will be the 
Fisher’s exact test.  Difference of the proportions and the 95% CI of the difference will be 
included.
Secondary  analyses for the co -primary efficacy measures PASI 75 and sPGA (0,1) will be 
conducted using a logistic regressio n anal ysis wit h treatment group, region, baseline sPGA score 
(severit y of the psori asis), and baseline weight category  (<25 kg, ≥25 to ≤50 kg, >50 kg) as 
factors.  The odds ratio and the corresponding 95% CIwill be reported.  
I1F-MC-RHCD (b)Clinical Protocol Page 107
LY2439821The primary analyses for the continuous efficacy and healt h outcomes variables will be made 
using analysis o f covariance (ANCOVA) and using a mixed model for repeated measures 
(MMRM) analysis). The ANCOVA model includes treatm ent, regi on, baseline sPGA score, 
baseli ne wei ght category , and baseline value.  Ty pe III sums of squares for the least squares 
means will be used for the statist ical com parison; the 95% CI will be reported.  
A secondary  analysis for continuous efficacy  and heal th outcom es variables will be mad e using a 
mixed model for repeated measures (MMRM) analysis.   When the MMRM is used, the model 
will include treatment, region, baseline sPGA score, baseline weight category , baseline val ue, 
visit, treatment -by-visit, and baseline -by-visit interactions as f ixed factors.  The covariance 
structure to model the within -subject errors will be unstructured.  The Kenward- Roger m ethod 
will be used to estimate the deno minator degrees of freedo m.  Type III tests for the least -squares 
means will be used for the statist ical com parison; the 95% CI will be reported.  Treatment 
comparisons at Week 12 and all other postbaseline visits in Period 2, Induction will be reported.  
If the unstructured covariance matrix results in a lack of convergence, the heterogeneous 
Toeplitz c ovari ance structure, followed by the heterogeneous autoregressive covariance 
structure, followed by the compound symmetry  will be used.  Thi s order is specified according to 
a decreasing number of covariance parameters in the structure.  The sandwich est imator (Di ggle 
et al. 1994) for the covariance est imation will be used by specifying the EMPIRICAL option in 
SAS PROC MIXED.  When sandwich est imation is used, the Kenward- Roger approximat ion for 
deno minator degrees of freedo m cannot be used.  Instead, DDFM= BETWITHIN opti on will be 
used to estimate deno minator degrees of freedo m.
Treatment comparisons of time to relapse (sPGA ≥ 2) will be conducted using the log -rank test 
as described in Protocol Addendum I1F- MC-RHCD(2).
Addit ional analyses and snapshots of study  data may  be performed during and/or after 
completion of Period 3 and/or Period 4 to fulfill the need for regulatory  interacti ons or 
publicat ion purposes.
10.4.8 Interim Analysis
Addit ional analyses and snapshots of study  data may  be performed during and/or after 
completion of Period 3 and/or Period 4 to fulfill the need for regulatory  interacti ons or 
publicat ion purposes.
Appendix 6. Protocol Amendment I1F -MC-RHCD(b) Summary:  
Multicenter, Double Double -Blind, Randomized, Placebo -Controlled 
Study to Evaluate Safety , Tolerability and Efficacy of Ixek izum ab in 
Patients from 6 to Less than 18 Years of Age with Moderate -to-
Severe Plaque Psoriasis
Leo Document ID = b7daa86f-0cf2-4c83-b4bf-b402c4428560
Approver: 
Approval Date & Time: 21-Sep-2018 19:31:15 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 22-Sep-2018 13:11:47 GMT
Signature meaning: Approved
PPD
PPD